S-3
As
filed with the Securities and Exchange Commission on April 3, 2009
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
AMICUS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
20-0422823 |
(State of incorporation)
|
|
(IRS Employer Identification Number) |
6 Cedar Brook Drive, Cranbury, NJ 08512
(609) 662-2000
(Address, including zip code, and telephone number, including area code, of registrants principal
executive offices)
John F. Crowley
Chief Executive Officer
Amicus Therapeutics, Inc.
6 Cedar Brook Drive
Cranbury, New Jersey 08512
(609) 662-2000
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Approximate date of commencement of proposed sale to the public:
From time to time after the effective date of this Registration Statement.
If the only securities being registered on this Form are being offered pursuant to dividend or
interest reinvestment plans, please check the following box. o
If any of the securities being registered on this Form are to be offered on a delayed or
continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities
offered only in connection with dividend or interest reinvestment plans, check the following
box. þ
If this Form is filed to register additional securities for an offering pursuant to Rule
462(b) under the Securities Act, please check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same
offering. o
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities
Act, please check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. o
If this Form is a registration statement pursuant to General Instruction I.D. or a
post-effective amendment thereto that shall become effective upon filing with the Commission
pursuant to Rule 462(e) under the Securities Act, check the following box. o
If this Form is a post-effective amendment to a registration statement filed pursuant to
General Instruction I.D. filed to register
additional securities or additional classes of securities pursuant to Rule 413(b) under the
Securities Act, check the following box. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,
a non-accelerated filer, or a smaller reporting company.
See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer o |
|
Accelerated filer o |
|
Non-accelerated filer þ
(Do not check if a smaller reporting company) |
|
Smaller reporting company o |
CALCULATION OF REGISTRATION FEE (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of each class of securities to be registered |
|
|
Proposed maximum offering price (1)(2) |
|
|
Amount of registration fee (2) |
|
|
Common Stock (3) |
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock (4) |
|
|
|
|
|
|
|
|
|
|
|
|
Warrants (5) |
|
|
|
|
|
|
|
|
|
|
|
|
Debt securities (6) |
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
$ |
100,000,000 |
|
|
|
$ |
5,580 |
|
|
|
|
|
|
(1) |
|
In no event will the aggregate offering price of all securities issued from time to time by the
registrant or sold by the selling stockholders under this registration statement exceed $100,000,000 or
its equivalent in any other currency, currency units, or composite currency or currencies. The
securities covered by this registration statement to be sold by the registrant may be sold separately,
together, or as units with other securities registered under this registration statement. The
securities to be resold by the selling stockholders will be shares of common stock only. |
|
(2) |
|
The proposed maximum aggregate price has been estimated solely for the purpose of calculating the
registration fee pursuant to Rule 457(o) under the Securities Act. |
|
(3) |
|
Subject to note (1), this registration statement covers an indeterminate amount of common stock (with
accompanying purchase rights, if any), as may be sold, from time to time, at indeterminate prices, by
the registrant or the selling stockholders, as the case may be. |
|
(4) |
|
Subject to note (1), this registration statement covers an indeterminate number of shares of preferred
stock (with accompanying purchase rights, if any), as may be sold, from time to time, at indeterminate
prices, by the registrant. Also covered is such an indeterminate amount of common stock (with
accompanying purchase rights, if any) (i) as may be issuable or deliverable upon conversion of shares of
preferred stock, and (ii) as may be required for delivery upon conversion of shares of preferred stock
as a result of anti-dilution provisions. |
|
(5) |
|
Subject to note (1), this registration statement covers an indeterminate amount and number of warrants
representing rights to purchase common stock, preferred stock and/or debt securities registered under
this registration statement, as may be sold, from time to time, at indeterminate prices by the
registrant. Also covered is an indeterminate amount of common stock and preferred stock (in each case,
with accompanying purchase rights, if any) and debt securities (i) as may be issuable or deliverable
upon exercise of warrants and (ii) as may be required for delivery upon exercise of any warrants as a
result of anti-dilution provisions. |
|
(6) |
|
Subject to note (1), this registration statement covers an indeterminate amount of debt securities, as
may be sold, from time to time, at indeterminate prices by the registrant. If any debt securities are
issued at an original issue discount, then the offering price shall be in such greater principal amount
as shall result in an aggregate initial offering price not to exceed $100,000,000. Also covered is an
indeterminate amount of common stock and preferred stock (in each case, with accompanying purchase
rights, if any) (i) as may be issuable or deliverable upon exercise or conversion of debt securities and
(ii) as may be required for delivery upon exercise or conversion of debt securities as a result of
anti-dilution provisions. |
We hereby amend this registration statement on such date or dates as may be necessary to delay its
effective date until we shall file a further amendment which specifically states that this
registration statement shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933 or until this registration statement shall become effective on such date as
the Commission, acting pursuant to said Section 8(a), may determine.
The information contained in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission
becomes effective. This prospectus is not an offer to sell these securities and we are not
soliciting offers to buy these securities in any jurisdiction where such offer or sale is not
permitted.
Subject
to Completion, Dated April 3, 2009
PROSPECTUS
$100,000,000
AMICUS THERAPEUTICS, INC.
Common Stock
Preferred Stock
Warrants
Debt Securities
We may offer to the public from time to time in one or more series or issuances:
|
|
|
shares of our common stock; |
|
|
|
|
shares of preferred stock; |
|
|
|
|
warrants to purchase shares of our common stock, preferred stock and/or debt securities; |
|
|
|
|
debt securities consisting of debentures, notes or other evidences of indebtedness; or |
|
|
|
|
any combination of these securities. |
Selling stockholders may also offer additional shares of our common stock from time to time.
This prospectus provides a general description of the securities that we or the selling
stockholders may offer. Each time that securities are sold under this prospectus, we will provide
specific terms of the securities offered in a supplement to this prospectus. The prospectus
supplement may also add, update or change information contained in this prospectus. This prospectus
may not be used to consummate a sale of securities unless accompanied by the applicable prospectus
supplement. You should read both this prospectus and the applicable prospectus supplement together
with additional information described under the heading Where You Can Find More Information
before you make your investment decision.
Securities sold under this prospectus shall be sold directly to purchasers or through agents
on our behalf or on behalf of the selling stockholders or through underwriters or dealers as
designated from time to time. If any agents or underwriters are involved in the sale of any of
these securities, the applicable prospectus supplement will provide the names of the agents or
underwriters and any applicable fees, commissions or discounts.
Our common stock is traded on the Nasdaq Global Market under the symbol FOLD. On March 23,
2009, the closing price of our common stock was $10.00.
As of March 23, 2009, the aggregate market value of our outstanding common stock held by
non-affiliates was approximately $106,307,120, based on 22,643,056 shares of outstanding common
stock, of which approximately 10,630,712 shares are held by non-affiliates, and a per share price
of $10.00 based on the closing sale price of our common stock on March 23, 2009. As of the date
hereof, we have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during
the prior 12 calendar month period that ends on and includes the date hereof.
Investing in our securities involves certain risks. Before investing, you should refer to the
risk factors on page 3 of this prospectus, included in our periodic reports, in prospectus
supplements and in other information filed by us with the Securities and Exchange Commission.
These securities have not been approved by the Securities and Exchange Commission or any state
securities commission, nor have these organizations determined that this prospectus is accurate or
complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is , 2009.
TABLE OF CONTENTS
Prospectus
ABOUT THIS PROSPECTUS
This prospectus is a part of a registration statement that we filed with the Securities and
Exchange Commission, or the SEC, using a shelf registration process. Under this shelf
registration process we may offer to sell any of the securities, or any combination of the
securities, described in this prospectus and the selling stockholders may offer to sell common
stock, in each case in one or more offerings up to a total dollar amount of $100,000,000.
This prospectus provides you only with a general description of the securities we or the
selling stockholders may offer. Each time securities are sold under this shelf registration, we
will provide a prospectus supplement that will contain specific information about the terms of
those securities and the terms of that offering. The prospectus supplement may also add, update or
change information contained in this prospectus. You should read both this prospectus and any
prospectus supplement, including all documents incorporated herein by reference, together with the
additional information described under Where You Can Find More Information below.
The information contained in this prospectus is not complete and may be changed. You should
rely only on the information provided in or incorporated by reference in this prospectus or in any
prospectus supplement, or documents to which we otherwise refer you. We have not authorized anyone
else to provide you with different information.
We have not authorized any dealer, agent or other person to give any information or to make
any representation other than those contained or incorporated by reference in this prospectus and
any accompanying prospectus supplement. You must not rely upon any information or representation
not contained or incorporated by reference in this prospectus or an accompanying prospectus
supplement. This prospectus and the accompanying prospectus supplement, if any, do not constitute
an offer to sell or the solicitation of an offer to buy any securities other than the registered
securities to which they relate, nor do this prospectus and the accompanying prospectus supplement
constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction
to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You
should not assume that the information contained in this prospectus and the accompanying prospectus
supplement, if any, is accurate on any date subsequent to the date set forth on the front of the
document or that any information we have incorporated by reference is correct on any date
subsequent to the date of the document incorporated by reference, even though this prospectus and
any accompanying prospectus supplement is delivered or securities are sold on a later date.
References in this prospectus to the terms the Company, Amicus, we, our and us or other
similar terms mean Amicus Therapeutics, Inc., unless we state otherwise or the context indicates
otherwise.
THE COMPANY
We are a clinical-stage biopharmaceutical company focused on the discovery, development and
commercialization of a new class of orally-administered, small molecule drugs, known as
pharmacological chaperones, for the treatment of a range of human genetic diseases. Our lead
product candidates in development are Amigal (migalastat hydrochloride) for Fabry disease, Plicera
(afegostat tartrate) for Gaucher disease and AT2220 (1-deoxynojirimycin HCl) for Pompe disease. We
completed our Phase 2 clinical trials of Amigal and are currently conducting Phase 2 clinical
trials of Plicera. We recently suspended a Phase 2 clinical trial of AT2220 and the IND is on
clinical hold pending FDA agreement to allow the Company to resume clinical development. Although
Fabry, Gaucher and Pompe are relatively rare diseases, they represent substantial commercial
markets due to the severity of the symptoms and the chronic nature of the diseases. The worldwide
net product sales for the five currently approved therapeutics to treat Fabry, Gaucher and Pompe
disease were approximately $2.2 billion in 2008, as publicly reported by the companies that market
these therapeutics.
Our goal is to become a leading biopharmaceutical company focused on the discovery,
development and commercialization of pharmacological chaperone therapies for the treatment of a
wide range of human diseases. Our initial clinical efforts are currently focused on developing
pharmacological chaperones for the treatment of lysosomal storage disorders, which are chronic
genetic diseases, such as Fabry, Gaucher and Pompe that frequently result in severe symptoms. We
also believe our technology may be broadly applicable to other diseases for which protein
stabilization and improved folding may be beneficial, including certain neurodegenerative and
genetically-based metabolic disorders.
Fabry, Gaucher and Pompe are among certain human diseases which result from mutations in
specific genes that, in many cases, lead to the production of proteins with reduced stability.
Proteins with such mutations may not fold into their correct three-dimensional shape and are
generally referred to as misfolded proteins. Misfolded proteins are often recognized by cells as
having defects and, as a result, may be eliminated prior to reaching their intended location in the
cell. The reduced biological activity of these proteins leads to impaired cellular function and
ultimately to disease.
Our novel approach to the treatment of human genetic diseases consists of using
pharmacological chaperones that selectively bind to the target protein; increasing the stability of
the protein and helping it fold into the correct three-dimensional shape. This allows proper
trafficking of the protein, thereby increasing protein activity, improving cellular function and
potentially reducing cell stress.
The current standard of treatment for Fabry, Gaucher and Pompe is enzyme replacement therapy
(ERT). This therapy compensates for the reduced level of activity of specialized proteins called
enzymes through regular infusions of recombinant enzyme. Instead of adding enzymes from an external
source by intravenous infusion, our approach uses small molecule, orally-administered
pharmacological chaperones to restore the function of the enzyme that is already made by the
patients own body. We believe our product candidates may have advantages relative to ERT relating
to bio-distribution and ease of use, potentially improving treatment of these diseases.
In order to further the development of our pharmacological chaperone therapies and share the
costs of such development, in November 2007, we entered into a strategic collaboration with Shire
Pharmaceuticals Ireland Ltd. (Shire), a subsidiary of Shire plc, to jointly develop our three lead
pharmacological chaperone compounds for lysosomal storage disorders. Shire will receive rights to
commercialize these products outside of the United States (U.S.). We retain all rights to
commercialize these products in the U.S.
Our principal executive offices are located at 6 Cedar Brook Drive, Cranbury, NJ 08512, and
our phone number is (609) 662-2000.
-2-
RISK FACTORS
Investing in our securities involves risk. The prospectus supplement applicable to each
offering of our securities will contain a discussion of the risks applicable to an investment in
us. Prior to making a decision about investing in our securities, you should carefully consider the
specific factors discussed under the heading Risk Factors in the applicable prospectus
supplement, together with all of the other information contained or incorporated by reference in
the prospectus supplement or appearing or incorporated by reference in this prospectus. You should
also consider the risks, uncertainties and assumptions discussed under the heading Risk Factors
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed on February 6,
2009, with the SEC, which is incorporated herein by reference, and may be amended, supplemented or
superseded from time to time by other reports we file with the SEC in the future. The risks and
uncertainties we have described are not the only ones we face. Additional risks and uncertainties
not presently known to us or that we currently deem immaterial may also affect our operations.
FORWARD-LOOKING STATEMENTS
This prospectus, any prospectus supplement and the other documents we have filed with the SEC
that are incorporated herein by reference contain forward-looking statements that involve
substantial risks and uncertainties. All statements, other than statements of historical facts,
regarding our strategy, future operations, future financial position, future revenues, projected
costs, prospects, plans, objectives of management or other financial items are forward-looking
statements. The words anticipate, believe, estimate, expect, intend, may, plan,
predict, project, will, would and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying
words.
We may not actually achieve the plans, intentions or expectations disclosed in our
forward-looking statements, and you should not place undue reliance on our forward-looking
statements. Actual results or events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements we make. We have included important
factors in the cautionary statements included in this prospectus, particularly as set forth and
incorporated by reference in the Risk Factors section above, that we believe could cause actual
results or events to differ materially from the forward-looking statements that we make. Our
forward-looking statements do not reflect the potential impact of any future acquisitions, mergers,
dispositions, joint ventures, collaborations or investments we may make.
You should read this prospectus, any supplements to this prospectus and the documents that we
incorporate by reference in this prospectus completely and with the understanding that our actual
future results may be materially different from what we expect. We do not assume any obligation to
update any forward-looking statements.
-3-
USE OF PROCEEDS
Except as otherwise provided in the applicable prospectus supplement, we intend to use the net
proceeds from the sale of the securities covered by this prospectus for general corporate purposes,
which may include working capital, capital expenditures, research and development expenditures,
clinical trial expenditures, commercial expenditures, acquisitions of new technologies or
businesses, and investments. Additional information on the use of net proceeds from the sale of
securities covered by this prospectus may be set forth in the prospectus supplement relating to the
specific offering. We will not receive any of the proceeds from the sale of any securities offered
by this prospectus by any selling stockholder.
RATIO OF EARNINGS TO COMBINED FIXED CHARGES (1)
The following table sets forth our ratio of earnings to fixed charges on a historical basis
for the periods indicated. For purposes of this calculation, earnings consists of net loss from
continuing operations plus fixed charges. Fixed charges consist of the sum of interest expense
and the estimate of interest within rental expense.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, |
|
|
2004 |
|
2005 |
|
2006 |
|
2007 |
|
2008 |
Ratio of Earnings
to Fixed Charges
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deficiency of
Earnings Available
to Cover Fixed Charges
(in millions) |
|
$ |
8.2 |
|
|
$ |
19.6 |
|
|
$ |
45.5 |
|
|
$ |
40.2 |
|
|
$ |
38.5 |
|
|
|
|
(1) |
|
For the years ended December 31, 2004, 2005, 2006, 2007 and 2008, earnings were insufficient
to cover fixed charges by $8.8 million, $20.0 million, $46.3 million, $41.2 million and $39.4
million, respectively. |
-4-
SELLING STOCKHOLDERS
The following table sets forth information regarding beneficial ownership of our common stock
as of February 18, 2009 by each person, or group of affiliated persons, known to us to be the
beneficial owner of more than 5% of our outstanding common stock, excluding our Directors and
Executive Officers.
Beneficial ownership is determined in accordance with the rules of the SEC, and includes
voting or investment power with respect to our common stock. The information contained in the
following table is not necessarily indicative of beneficial ownership for any other purpose and the
inclusion of any shares in the table does not constitute an admission of beneficial ownership of
those shares.
The selling stockholders or their successors, including transferees, may from time to time
offer and sell, pursuant to this prospectus or a supplement to this prospectus, any or all of the
shares of our common stock that they own. Further details on any selling stockholder will be
included in the relevant prospectus supplement.
Unless otherwise indicated below, to our knowledge, all persons named in the table have sole
voting and investment power with respect to their shares of common stock, except to the extent
authority is shared by spouses under community property laws.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares Beneficially Owned |
|
|
|
|
|
|
Shares Beneficially Owned |
|
|
|
Prior to Offering |
|
|
|
|
|
|
After Offering |
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
|
|
|
|
|
Name and Address of Beneficial Owner |
|
Number |
|
|
Percentage |
|
|
Offered |
|
|
Number |
|
|
Percentage |
|
5% Stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Entities affiliated with New Enterprise Associates (1) |
|
|
4,510,340 |
|
|
|
19.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
1119 St. Paul Street
Baltimore, MD 21202 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Entities affiliated with Frazier Healthcare Ventures (2) |
|
|
3,520,678 |
|
|
|
15.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
601 Union, Two Union Square, Suite 3200
Seattle, WA 98101 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Entities affiliated with Palo Alto Investors (3) |
|
|
3,014,998 |
|
|
|
13.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
470 University Avenue
Palo Alto, CA 94301 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Entities affiliated with Prospect Venture Partners II, L.P. (4) |
|
|
2,240,752 |
|
|
|
9.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
435 Tasso Street, Suite 200
Palo Alto, CA 94301 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Entities affiliated with CHL Medical Partners (5) |
|
|
2,058,554 |
|
|
|
9.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
1055 Washington Boulevard, 6th Floor
Stamford, CT 06901 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Entities affiliated with Canaan Partners (6) |
|
|
1,714,090 |
|
|
|
7.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
285 Riverside Avenue, Suite 250
Westport, CT 06880 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Entities affiliated with Quaker BioVentures (7) |
|
|
1,419,762 |
|
|
|
6.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
Cira Center
2929 Arch Street
Philadelphia, PA 19104-2868 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Entities affiliated with Baker Brothers Life Sciences, L.P. (8) |
|
|
1,338,193 |
|
|
|
5.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
667 Madison Avenue, 17th Floor
New York, NY 10065 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Consists of 3,659,157 shares held of record by New Enterprise Associates 11, Limited
Partnership and
851,183 shares held of record by New Enterprise Associates 9, Limited Partnership. Voting and investment power over the shares held by
New Enterprise Associates 9, Limited Partnership is exercised by NEA Partners 9, Limited
Partnership, its general partner. The individual general partners of NEA Partners 9, Limited
Partnership are C. Richard Kramlich, Peter J. Barris, Charles W. Newhall, III, Mark W. Perry
and John M. Nehra. Voting and investment power over the shares held by New Enterprise
Associates 11, Limited Partnership is exercised by NEA Partners 11, Limited Partnership, its
general partner. The general partner of NEA Partners 11, Limited Partnership is NEA 11 GP,
LLC. The individual managers of NEA 11 GP, LLC are C. Richard Kramlich, Peter J. Barris,
Forest Baskett, Charles W. Newhall, III, Mark W. Perry, Scott D. Sandell, Eugene A. Trainor,
III, Charles M. Linehan, Ryan D. Drant, Krishna Kittu Kolluri and M. James Barrett. Each of the aforementioned indirect holders of the shares held by New Enterprise |
-5-
|
|
|
|
|
Associates 11, Limited Partnership and New Enterprise Associates 9, Limited Partnership disclaims beneficial ownership of such shares, except to
the extent of their respective pecuniary interest therein. |
|
(2) |
|
Consists of 2,586,886 shares held of record by Frazier Healthcare IV, L.P., 13,128 shares held
of record by Frazier Affiliates IV, L.P. and 920,664 shares held of record by Frazier
Affiliates V, L.P. Dr. Topper, a member of our Board of Directors, holds the title of General
Partner with Frazier Healthcare Ventures. In that capacity he shares voting and investment
power for the shares held by both Frazier Healthcare IV, L.P. and Frazier Affiliates IV, L.P.
Dr. Topper disclaims beneficial ownership of the shares held by entities affiliated with
Frazier Healthcare Ventures, except to the extent of any pecuniary interest therein. |
|
(3) |
|
Consists of 3,014,998 shares held of record by Palo Alto Investors, LLC, 1,627,606 shares held
of record by Palo Alto Healthcare Master Fund, L.P., 1,204,917 shares held of record by Palo
Alto Healthcare Fund, L.P. Palo Alto Investors is the manager of Palo Alto Investors, LLC.
Mr. Edwards is the controlling shareholder of Palo Alto Investors. Dr. Yun is the President
of Palo Alto Investors, LLC and Palo Alto Investors. Each of Palo Alto Investors, LLC, Palo
Alto Investors, Mr. Edwards and Dr. Yun disclaims beneficial ownership of the Stock except to
the extent of that Filers pecuniary interest therein. |
|
(4) |
|
Consists of 2,207,144 shares held of record by Prospect Venture Partners II, L.P., and 33,608
shares held of record by Prospect Associates II, L.P. Dr. Barkas, a member of our board of
directors and a Managing Member of the General partner of both Prospect Venture Partners II,
L.P. and Prospect Associates II, L.P., disclaims beneficial ownership
of the shares held by entities affiliated with Prospect Venture Partners II, L.P. except, to the extent of any
pecuniary interest therein. |
|
(5) |
|
Consists of 1,928,611 shares held of record by CHL Medical Partners II, L.P. and 129,943
shares of record held by CHL Medical Partners II Side Fund, L.P. Voting and investment power
over the shares held by each of the partnerships constituting CHL Medical Partners is
exercised by Collinson Howe & Lennox II, L.L.C. in its role as general partner and investment
advisor to the partnerships. The members of Collinson Howe & Lennox II, L.L.C. are Jeffrey J.
Collinson, Myles D. Greenberg, Timothy F. Howe, Ronald W. Lennox and Gregory M. Weinoff, a
member of our board of directors. Each of these members disclaims beneficial ownership of
these shares except tot eh extent of his proportionate pecuniary interest therein. |
|
(6) |
|
Consists of 1,652,390 shares held of record by Canaan Equity III, L.P., and 61,700 shares held
of record by Canaan Equity III Entrepreneurs, LLC. Canaan Equity Partners III, LLC, the sole
general partner of Canaan Equity III, L.P. and sole manager of Canaan Equity III
Entrepreneurs, LLC, has sole voting and disposition power over these shares. The Managers of
Canaan Equity Partners III, LLC are John V. Balen, Stephen L. Green, Deepak Kamra, Gregory
Kopchinsly, Seth A. Rudnick, Guy M. Russo and Eric A. Young. Dr. Bloch, a member of our board
of directors, is a member of Canaan Equity Partners III, LLC. Dr. Bloch does not have sole or
shared voting or disposition power over these shares. |
|
(7) |
|
Consists of 1,064,822 shares held of record by Quaker BioVentures, L.P. and 354,940 shares of
record held by Garden State Lice Sciences Venture Fund, L.P. Mr. Neff, a member of our board
of directors and a Member of the General Partner of both Quaker BioVentures, L.P. and Garden
State Life Sciences Venture Fund, L.P. disclaims beneficial ownership of the shares held by
entities affiliated with Quaker BioVentures, except to the extent of any pecuniary interest
therein. |
|
(8) |
|
Consists of 331 shares held of record by Baker Bros. Investments II, L.P., 331,437 shares held
of record by 667, L.P., 970,445 shares held of record by Baker Brothers Life Sciences, L.P.,
30,844 shares held of record by 14159, L.P., 5,079 shares held of record by Baker/Tisch
Investments, L.P., and 57 shares held of record by FBB Associates. By virtue of their
ownership of entities that have the power to control the investment decisions of the limited
partnerships listed above, Felix J. Baker and Julian C. Baker may each be deemed to be
beneficial owners of shares owned by such entities and may be deemed to have shared power to
vote or direct the vote of and shared power to dispose or direct the disposition of such
securities. |
The preceding table represents the holdings by the selling stockholders, based solely on
information set forth in their respective public filings. Information concerning the selling
stockholders may change from time to time, which changed information will be set forth in
supplements to this prospectus.
We do not know when or in what amounts the selling stockholders may offer the securities for
sale. The selling stockholders might not sell any or all of the securities offered by this
prospectus. Because the selling stockholders may offer all or some of the securities pursuant to
this offering, and because currently no sale of any of the securities is subject to any agreements,
arrangements or understandings, we cannot estimate the number of the securities that will be held
by the selling stockholders after completion of the offering.
-6-
Certain Relationships and Related Party Transactions
Investor Rights Agreement
Pursuant to a third amended and restated investor rights agreement, dated as of September 13,
2006, by and among entities who held our redeemable convertible preferred stock (which was
converted to common stock at our initial public offering) and us, we granted registration rights to
all such holders, to Mount Sinai School of Medicine of New York University, or MSSM, and to the
holder of a warrant which has since been exercised. Entities affiliated with Prospect Venture
Partners II, L.P., New Enterprise Associates, Frazier Healthcare Ventures, Canaan Equity, Quaker
BioVentures, CHL Medical Partners and Palo Alto Investors, LLC, each a holder of 5% or more of our
voting securities, and their affiliates are parties to this investor rights agreement.
Subject to certain limitations, these stockholders may demand that, on up to two occasions, we
register all or part of their securities for sale under the Securities Act as long as the aggregate
price to the public for the securities to be sold in each instance is $5,000,000 or more. If we
are eligible to register any of our common stock on Form S-3, these stockholders may make the same
demand; provided, however, that we will not be required to register their securities if (i) we have
already effected a registration within 90 days prior to the request or have effected two or more
registrations on Form S-3 within the preceding 12 month period, or (ii) if the aggregate price to
the public for the securities to be sold is less than $2,500,000. Additionally, if we believe that
such registration would have a materially detrimental effect on any material corporate event, we
may delay the request for up to three months, but not more than once in any twelve month period.
These stockholders may also request registration of their shares if we register any of our
common stock, either for our own account or for the account of other securityholders. In such an
event, these stockholders are entitled to notice of the registration and to include their shares of
common stock in such registration. In the case of an underwritten registration, we must use our
reasonable best efforts to obtain the permission of the underwriters to the inclusion of the
holders shares in the offering on the same terms.
With specified exceptions, a holders right to include shares in a registration is subject to
the right of the underwriters to limit the number of shares included in the offering. All fees,
costs and expenses of any registrations will generally be paid by us.
Mt. Sinai School of Medicine License Agreement
We acquired exclusive worldwide patent rights to develop and commercialize our lead products
and other pharmacological chaperones pursuant to a license agreement with MSSM. In connection with
this agreement, we issued 232,266 shares of our common stock to MSSM in April 2002. In October 2006
we issued MSSM an additional 133,333 shares of common stock and made a payment of $1.0 million in
consideration of an expanded field of use under that license. Under this agreement, to date we have
paid no upfront or annual license fees and we have no milestone or future payments other than
royalties on net sales. However, on October 31, 2008, we amended and restated this license
agreement to, among other items, provide us with the sole right to control the prosecution of
patent rights under such agreement and to clarify the portion of royalties and milestone payments
we receive from Shire Pharmaceuticals Ireland Ltd. that are payable to MSSM. In connection
therewith, we agreed to pay MSSM $2.6 million in connection with the $50 million upfront payment
that we received in November 2007 from Shire and an additional $2.6 million for the sole right to
and control over the prosecution of patent rights. This agreement expires upon expiration of the
last of the licensed patent rights, which will be in 2019 if a foreign patent is granted and 2018
otherwise, or later subject to any patent term extension that may be granted.
-7-
PLAN OF DISTRIBUTION
Amicus, and any selling stockholders and their successors, including their permitted
transferees, may sell the offered securities in any of the ways described below or in any
combination or any other way set forth in an applicable prospectus supplement from time to time:
|
|
|
to or through underwriters or dealers; |
|
|
|
|
through one or more agents; or |
|
|
|
|
directly to purchasers or to a single purchaser. |
The distribution of the securities may be effected from time to time in one or more
transactions:
|
|
|
at a fixed price, or prices, which may be changed from time to time; |
|
|
|
|
at market prices prevailing at the time of sale; |
|
|
|
|
at prices related to such prevailing market prices; or |
|
|
|
|
at negotiated prices. |
Each prospectus supplement will describe the method of distribution of the securities and any
applicable restrictions.
The prospectus supplement with respect to the securities of a particular series will describe
the terms of the offering of the securities, including the following:
|
|
|
the name or names of any underwriters, dealers or agents and the
amounts of securities underwritten or purchased by each of them; |
|
|
|
|
the public offering price of the securities and the proceeds to us and
any discounts, commissions or concessions allowed or reallowed or paid
to dealers; and |
|
|
|
|
any securities exchanges on which the securities may be listed. |
Any offering price and any discounts or concessions allowed or reallowed or paid to dealers
may be changed from time to time.
Only the agents or underwriters named in each prospectus supplement are agents or underwriters
in connection with the securities being offered thereby.
We may authorize underwriters, dealers or other persons acting as our agents to solicit offers
by certain institutions to purchase securities from us pursuant to delayed delivery contracts
providing for payment and delivery on the date stated in each applicable prospectus supplement.
Each contract will be for an amount not less than, and the aggregate amount of securities sold
pursuant to such contracts shall not be less nor more than, the respective amounts stated in each
applicable prospectus supplement. Institutions with whom the contracts, when authorized, may be
made include commercial and savings banks, insurance companies, pension funds, investment
companies, educational and charitable institutions and other institutions, but shall in all cases
be subject to our approval. Delayed delivery contracts will be subject only to those conditions set
forth in each applicable prospectus supplement, and each prospectus supplement will set forth any
commissions we pay for solicitation of these contracts.
Agents, underwriters and other third parties described above may be entitled to
indemnification by us or any selling stockholder against certain civil liabilities, including
liabilities under the Securities Act of 1933, or to contribution from us with respect to payments
which the agents, underwriters or other third parties may be required to make in respect thereof.
Agents, underwriters and such other third parties may be customers of, engage in transactions with,
or perform services for us in the ordinary course of business.
One or more firms, referred to as remarketing firms, may also offer or sell the securities,
if a prospectus supplement so indicates, in connection with a remarketing arrangement upon their
purchase. Remarketing firms will act as principals for their own accounts or as our agents. These
remarketing firms will offer or sell the securities in accordance with the terms of the securities.
Each prospectus supplement will identify and describe any remarketing firm and the terms of its
agreement, if any, with us and will describe the remarketing firms compensation. Remarketing firms
may be deemed to be underwriters in connection with the securities they remarket. Remarketing firms
may be entitled under agreements that may be entered into with us to indemnification by us against
-8-
certain civil liabilities, including liabilities under the Securities Act of 1933, and may be
customers of, engage in transactions with or perform services for us in the ordinary course of
business.
Certain underwriters may use this prospectus and any accompanying prospectus supplement for
offers and sales related to market-making transactions in the securities. These underwriters may
act as principal or agent in these transactions, and the sales will be made at prices related to
prevailing market prices at the time of sale.
The securities we or any selling stockholders offer may be new issues of securities and may
have no established trading market. The securities may or may not be listed on a securities
exchange. Underwriters may make a market in these securities, but will not be obligated to do so
and may discontinue any market making at any time without notice. We can make no assurance as to
the liquidity of, or the existence of trading markets for, any of the securities.
Certain persons participating in an offering may engage in overallotment, stabilizing
transactions, short covering transactions and penalty bids in accordance with rules and regulations
under the Securities Exchange Act of 1934. Overallotment involves sales in excess of the offering
size, which create a short position. Stabilizing transactions permit bids to purchase the
underlying security so long as the stabilizing bids do not exceed a specified maximum. Short
covering transactions involve purchases of the securities in the open market after the distribution
is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling
concession from a dealer when the securities originally sold by the dealer are purchased in a short
covering transaction to cover short positions. Those activities may cause the price of the
securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue
any of the activities at any time.
We also may sell any of the securities through agents designated by us from time to time. We
will name any agent involved in the offer or sale of these securities and will list commissions
payable by us to these agents in the applicable prospectus supplement. These agents will be acting
on a best efforts basis to solicit purchases for the period of its appointment, unless stated
otherwise in the applicable prospectuses.
We or any selling stockholders may sell any of the securities directly to purchasers. In this
case, we or any selling stockholders will not engage underwriters or agents in the offer and sale
of these securities.
-9-
GENERAL DESCRIPTION OF SECURITIES
We may offer and sell, at any time and from time to time:
|
|
|
Shares of our common stock; |
|
|
|
|
Shares of our preferred stock; |
|
|
|
|
Warrants to purchase shares of our common stock, preferred stock and/or debt
securities; |
|
|
|
|
Debt securities consisting of debentures, notes or other evidences of indebtedness;
or |
|
|
|
|
Any combination of these securities. |
The selling stockholders may also offer additional shares of or common stock form time to
time. The terms of any securities we offer or offered by the selling stockholders will be
determined at the time of sale. We may issue debt securities that are exchangeable for and/or
convertible into common stock or any of the other securities that may be sold under this
prospectus. When particular securities are offered, a supplement to this prospectus will be filed
with the SEC, which will describe the terms of the offering and sale of the offered securities.
-10-
DESCRIPTION OF OUR COMMON STOCK
The following summary of the terms of our common stock is subject to and qualified in its
entirety by reference to our charter and by-laws, copies of which are on file with the SEC as
exhibits to previous SEC filings. Please refer to Where You Can Find More Information below for
directions on obtaining these documents.
As of March 23, 2009, we are authorized to issue 50,000,000 shares of common stock, $0.01 par
value per share. As of March 23, 2009, we had 22,643,056 shares of common stock outstanding.
General
Holders of our common stock are entitled to one vote for each share held on all matters
submitted to a vote of stockholders and do not have cumulative voting rights. An election of
directors by our stockholders shall be determined by a plurality of the votes cast by the
stockholders entitled to vote on the election. Holders of common stock are entitled to receive
proportionately any dividends as may be declared by our board of directors, subject to any
preferential dividend rights of any outstanding preferred stock.
In the event of our liquidation or dissolution, the holders of common stock are entitled to
receive proportionately all assets available for distribution to stockholders after the payment of
all debts and other liabilities and subject to the prior rights of any outstanding preferred stock.
Holders of common stock have no preemptive, subscription, redemption or conversion rights. The
rights, preferences and privileges of holders of common stock are subject to and may be adversely
affected by the rights of the holders of shares of any series of preferred stock that we may
designate and issue in the future.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is American Stock Transfer and Trust
Company.
The NASDAQ Global Market
Our common stock is listed on the Nasdaq Global Market under the symbol FOLD.
-11-
DESCRIPTION OF OUR PREFERRED STOCK
We are authorized to issue up to 10,000,000 shares of preferred stock, par value $0.01 per
share. As of March 23, 2009, there were no shares of our preferred stock outstanding.
Our board of directors may, without further action by our stockholders, from time to time,
direct the issuance of shares of preferred stock in series and may, at the time of issuance,
determine the rights, preferences and limitations of each series, including voting rights, dividend
rights and redemption and liquidation preferences. Satisfaction of any dividend preferences of
outstanding shares of our preferred stock would reduce the amount of funds available for the
payment of dividends on shares of our common stock. Holders of shares of our preferred stock may be
entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up
of our Company before any payment is made to the holders of shares of our common stock. In some
circumstances, the issuance of shares of preferred stock may render more difficult or tend to
discourage a merger, tender offer or proxy contest, the assumption of control by a holder of a
large block of our securities or the removal of incumbent management. Upon the affirmative vote of
our board of directors, without stockholder approval, we may issue shares of preferred stock with
voting and conversion rights which could adversely affect the holders of shares of our common
stock.
If we offer a specific class or series of preferred stock under this prospectus, we will
describe the terms of the preferred stock in the prospectus supplement for such offering and will
file a copy of the certificate establishing the terms of the preferred stock with the SEC. To the
extent required, this description will include:
|
|
|
the title and stated value; |
|
|
|
|
the number of shares offered, the liquidation preference per share and the purchase
price; |
|
|
|
|
the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation
for such dividends; |
|
|
|
|
whether dividends will be cumulative or non-cumulative and, if cumulative, the date
from which dividends will accumulate; |
|
|
|
|
the procedures for any auction and remarketing, if any; |
|
|
|
|
the provisions for a sinking fund, if any; |
|
|
|
|
the provisions for redemption, if applicable; |
|
|
|
|
any listing of the preferred stock on any securities exchange or market; |
|
|
|
|
whether the preferred stock will be convertible into our common stock, and, if
applicable, the conversion price (or how it will be calculated), the conversion period and
any other terms of conversion (including any anti-dilution provisions, if any); |
|
|
|
|
whether the preferred stock will be exchangeable into debt securities, and, if
applicable, the exchange price (or how it will be calculated), the exchange period and any
other terms of exchange (including any anti-dilution provisions, if any); |
|
|
|
|
voting rights, if any, of the preferred stock; |
|
|
|
|
a discussion of any material U.S. federal income tax considerations applicable to the
preferred stock; |
|
|
|
|
the relative ranking and preferences of the preferred stock as to dividend rights and
rights upon liquidation, dissolution or winding up of the affairs of the Company; |
|
|
|
|
any material limitations on issuance of any class or series of preferred stock
ranking senior to or on a parity with the series of preferred stock as to dividend rights
and rights upon liquidation, dissolution or winding up of the Company; and |
|
|
|
|
any other affirmative, negative or other covenants or contractual rights which might
be attendant with the specific class or series of preferred stock. |
The preferred stock offered by this prospectus, when issued, will not have, or be subject to,
any preemptive or similar rights.
Transfer Agent and Registrar
The transfer agent and registrar for any series or class of preferred stock will be set forth
in each applicable prospectus supplement.
-12-
DESCRIPTION OF OUR WARRANTS
We may issue warrants to purchase shares of our common stock, preferred stock and/or debt
securities in one or more series together with other securities or separately, as described in each
applicable prospectus supplement. Below is a description of certain general terms and provisions of
the warrants that we may offer. Particular terms of the warrants will be described in the
applicable warrant agreements and the applicable prospectus supplement for the warrants.
The applicable prospectus supplement will contain, where applicable, the following terms of
and other information relating to the warrants:
|
|
|
the specific designation and aggregate number of, and the price at which we will
issue, the warrants; |
|
|
|
|
the currency or currency units in which the offering price, if any, and the exercise
price are payable; |
|
|
|
|
the designation, amount and terms of the securities purchasable upon exercise of the
warrants; |
|
|
|
|
if applicable, the exercise price for shares of our common stock and the number of shares of common stock to be received upon exercise of the warrants; |
|
|
|
|
if applicable, the exercise price for shares of our preferred stock, the number of
shares of preferred stock to be received upon exercise, and a description of that class or
series of our preferred stock; |
|
|
|
|
if applicable, the exercise price for our debt securities, the amount of our debt
securities to be received upon exercise, and a description of that series of debt
securities; |
|
|
|
|
the date on which the right to exercise the warrants will begin and the date on which
that right will expire or, if the warrants may not be continuously exercised throughout
that period, the specific date or dates on which the warrants may be exercised; |
|
|
|
|
whether the warrants will be issued in fully registered form or bearer form, in
definitive or global form or in any combination of these forms, although, in any case, the
form of a warrant included in a unit will correspond to the form of the unit and of any
security included in that unit; |
|
|
|
|
any applicable material U.S. federal income tax consequences; |
|
|
|
|
the identity of the warrant agent for the warrants and of any other depositaries,
execution or paying agents, transfer agents, registrars or other agents; |
|
|
|
|
the proposed listing, if any, of the warrants or any securities purchasable upon
exercise of the warrants on any securities exchange; |
|
|
|
|
if applicable, the date from and after which the warrants and the common stock,
preferred stock and/or debt securities will be separately transferable; |
|
|
|
|
if applicable, the minimum or maximum amount of the warrants that may be exercised at
any one time; |
|
|
|
|
information with respect to book-entry procedures, if any; |
|
|
|
|
the anti-dilution provisions of the warrants, if any; |
|
|
|
|
any redemption or call provisions; |
|
|
|
|
whether the warrants are to be sold separately or with other securities as parts of
units; and |
|
|
|
|
any additional terms of the warrants, including terms, procedures and limitations
relating to the exchange and exercise of the warrants. |
Transfer Agent and Registrar
The transfer agent and registrar for any warrants will be set forth in the applicable
prospectus supplement.
-13-
DESCRIPTION OF OUR DEBT SECURITIES
This section describes the general terms and provisions of the debt securities that we may
offer under this prospectus, any of which may be issued as convertible or exchangeable debt
securities. We will set forth the particular terms of the debt securities we offer in a prospectus
supplement. The extent, if any, to which the following general provisions apply to particular debt
securities will be described in the applicable prospectus supplement. The following description of
general terms relating to the debt securities and the indenture under which the debt securities
will be issued are summaries only and therefore are not complete. You should read the indenture and
the prospectus supplement regarding any particular issuance of debt securities.
We will issue any debt under an indenture to be entered into between us and the trustee
identified in the applicable prospectus supplement. The terms of the debt securities will include
those stated in the indenture and those made part of the indenture by reference to the Trust
Indenture Act of 1939, as in effect on the date of the indenture. We have filed or will file a copy
of the form of indenture as an exhibit to the registration statement in which this prospectus is
included. The indenture will be subject to and governed by the terms of the Trust Indenture Act of
1939.
We may offer under this prospectus up to an aggregate principal amount of $100,000,000 in debt
securities, or if debt securities are issued at a discount, or in a foreign currency, foreign
currency units or composite currency, the principal amount as may be sold for an initial public
offering price of up to $100,000,000. Unless otherwise specified in the applicable prospectus
supplement, the debt securities will represent direct, unsecured obligations of the Company and
will rank equally with all of our other unsecured indebtedness.
The following statements relating to the debt securities and the indenture are summaries,
qualified in their entirety by reference to the detailed provisions of the indenture and the final
form indenture as may be filed with a future prospectus supplement.
General
We may issue the debt securities in one or more series with the same or various maturities, at
par, at a premium, or at a discount. We will describe the particular terms of each series of debt
securities in a prospectus supplement relating to that series, which we will file with the SEC.
The prospectus supplement will set forth, to the extent required, the following terms of the
debt securities in respect of which the prospectus supplement is delivered:
|
|
|
the title of the series; |
|
|
|
|
the aggregate principal amount; |
|
|
|
|
the issue price or prices, expressed as a percentage of the aggregate principal
amount of the debt securities; |
|
|
|
|
any limit on the aggregate principal amount; |
|
|
|
|
the date or dates on which principal is payable; |
|
|
|
|
the interest rate or rates (which may be fixed or variable) or, if applicable, the
method used to determine such rate or rates; |
|
|
|
|
the date or dates from which interest, if any, will be payable and any regular
record date for the interest payable; |
|
|
|
|
the place or places where principal and, if applicable, premium and interest, is
payable; |
|
|
|
|
the terms and conditions upon which we may, or the holders may require us to, redeem
or repurchase the debt securities; |
|
|
|
|
the denominations in which such debt securities may be issuable, if other than
denominations of $1,000 or any integral multiple of that number; |
|
|
|
|
whether the debt securities are to be issuable in the form of certificated
securities (as described below) or global securities (as described below); |
|
|
|
|
the portion of principal amount that will be payable upon declaration of
acceleration of the maturity date if other than the principal amount of the debt
securities; |
|
|
|
|
the currency of denomination; |
|
|
|
|
the designation of the currency, currencies or currency units in which payment of
principal and, if applicable, premium and interest, will be made; |
-14-
|
|
|
if payments of principal and, if applicable, premium or interest, on the debt
securities are to be made in one or more currencies or currency units other than the
currency of denomination, the manner in which the exchange rate with respect to such
payments will be determined; |
|
|
|
|
if amounts of principal and, if applicable, premium and interest may be determined
by reference to an index based on a currency or currencies or by reference to a
commodity, commodity index, stock exchange index or financial index, then the manner in
which such amounts will be determined; |
|
|
|
|
the provisions, if any, relating to any collateral provided for such debt
securities; |
|
|
|
|
any addition to or change in the covenants and/or the acceleration provisions
described in this prospectus or in the indenture; |
|
|
|
|
any events of default, if not otherwise described below under Events of Default; |
|
|
|
|
the terms and conditions, if any, for conversion into or exchange for shares of our
common stock or preferred stock; |
|
|
|
|
any depositaries, interest rate calculation agents, exchange rate calculation agents
or other agents; and |
|
|
|
|
the terms and conditions, if any, upon which the debt securities shall be
subordinated in right of payment to other indebtedness of the Company. |
We may issue discount debt securities that provide for an amount less than the stated
principal amount to be due and payable upon acceleration of the maturity of such debt securities in
accordance with the terms of the indenture. We may also issue debt securities in bearer form, with
or without coupons. If we issue discount debt securities or debt securities in bearer form, we will
describe material U.S. federal income tax considerations and other material special considerations
which apply to these debt securities in the applicable prospectus supplement.
We may issue debt securities denominated in or payable in a foreign currency or currencies or
a foreign currency unit or units. If we do, we will describe the restrictions, elections, and
general tax considerations relating to the debt securities and the foreign currency or currencies
or foreign currency unit or units in the applicable prospectus supplement.
Exchange and/or Conversion Rights
We may issue debt securities which can be exchanged for or converted into shares of our common
stock or preferred stock. If we do, we will describe the terms of exchange or conversion in the
prospectus supplement relating to these debt securities.
Transfer and Exchange
We may issue debt securities that will be represented by either:
|
|
|
book-entry securities, which means that there will be one or more global securities
registered in the name of a depositary or a nominee of a depositary; or |
|
|
|
|
certificated securities, which means that they will be represented by a certificate
issued in definitive registered form. |
We will specify in the prospectus supplement applicable to a particular offering whether the
debt securities offered will be book-entry or certificated securities.
Certificated Debt Securities
If you hold certificated debt securities issued under an indenture, you may transfer or
exchange such debt securities in accordance with the terms of the indenture. You will not be
charged a service charge for any transfer or exchange of certificated debt securities but may be
required to pay an amount sufficient to cover any tax or other governmental charge payable in
connection with such transfer or exchange.
Global Securities
The debt securities of a series may be issued in the form of one or more global securities
that will be deposited with a depositary or its nominees identified in the prospectus supplement
relating to the debt securities. In such a case, one or more global securities will be issued in a
denomination or aggregate denominations equal to the portion of the aggregate principal amount of
outstanding debt securities of the series to be represented by such global security or securities.
Unless and until it is exchanged in whole or in part for debt securities in definitive
registered form, a global security may not be registered for transfer or exchange except as a whole
by the depositary for such global security to a nominee of the depositary and except in the
circumstances described in the prospectus supplement relating to the debt securities. The specific
terms of the depositary
-15-
arrangement with respect to a series of debt securities will be described in the prospectus
supplement relating to such series.
No Protection in the Event of Change of Control
Any indenture that governs our debt securities covered by this prospectus may not have any
covenant or other provision providing for a put or increased interest or otherwise that would
afford holders of our debt securities additional protection in the event of a recapitalization
transaction, a change of control of the Company, or a highly leveraged transaction. If we offer any
covenants or provisions of this type with respect to any debt securities covered by this
prospectus, we will describe them in the applicable prospectus supplement.
Covenants
Unless otherwise indicated in this prospectus or the applicable prospectus supplement, our
debt securities may not have the benefit of any covenant that limits or restricts our business or
operations, the pledging of our assets or the incurrence by us of indebtedness. We will describe in
the applicable prospectus supplement any material covenants in respect of a series of debt
securities.
Consolidation, Merger and Sale of Assets
We may agree in any indenture that governs the debt securities of any series covered by this
prospectus that we will not consolidate with or merge into any other person or convey, transfer,
sell or lease our properties and assets substantially as an entirety to any person, unless such
person and such proposed transaction meets various criteria, which we will describe in detail in
the applicable prospectus supplement.
Defaults and Notice
The debt securities of any series will contain events of default to be specified in the
applicable prospectus supplement, which may include, without limitation:
|
|
|
failure to pay the principal of, or premium or make-whole amount, if any, on any
debt security of such series when due and payable (whether at maturity, by call for
redemption, through any mandatory sinking fund, by redemption at the option of the
holder, by declaration or acceleration or otherwise); |
|
|
|
|
failure to make a payment of any interest on any debt security of such series when
due; |
|
|
|
|
our failure to perform or observe any other covenants or agreements in the indenture
with respect to the debt securities of such series; |
|
|
|
|
certain events relating to our bankruptcy, insolvency or reorganization; and |
|
|
|
|
certain cross defaults, if and as applicable. |
If an event of default with respect to debt securities of any series shall occur and be
continuing, we may agree that the trustee or the holders of at least 25% in aggregate principal
amount of the then outstanding debt securities of such series may declare the principal amount (or,
if the debt securities of such series are issued at an original issue discount, such portion of the
principal amount as may be specified in the terms of the debt securities of such series) of all
debt securities of such series or such other amount or amounts as the debt securities or
supplemental indenture with respect to such series may provide, to be due and payable immediately.
Any provisions pertaining to events of default and any remedies associated therewith will be
described in the applicable prospectus supplement.
Any indenture that governs our debt securities covered by this prospectus may require that the
trustee under such indenture shall, within 90 days after the occurrence of a default, give to
holders of debt securities of any series notice of all uncured defaults with respect to such series
known to it. However, in the case of a default that results from the failure to make any payment of
the principal of, premium or make-whole amount, if any, or interest on the debt securities of any
series, or in the payment of any mandatory sinking fund installment with respect to debt securities
of such series, if any, the trustee may withhold such notice if it in good faith determines that
the withholding of such notice is in the interest of the holders of debt securities of such series.
Any terms and provisions relating to the foregoing types of provisions will be described in
further detail in the applicable prospectus supplement.
Any indenture that governs our debt securities covered by this prospectus will contain a
provision entitling the trustee to be indemnified by holders of debt securities before proceeding
to exercise any trust or power under the indenture at the request of such holders. Any such
indenture may provide that the holders of at least a majority in aggregate principal amount of the
then outstanding debt securities of any series may direct the time, method and place of conducting
any proceedings for any remedy available to the trustee, or of exercising any trust or power
conferred upon the trustee with respect to the debt securities of such series. However, the
-16-
trustee under any such indenture may decline to follow any such direction if, among other
reasons, the trustee determines in good faith that the actions or proceedings as directed may not
lawfully be taken, would involve the trustee in personal liability or would be unduly prejudicial
to the holders of the debt securities of such series not joining in such direction.
Any indenture that governs our debt securities covered by this prospectus may endow the
holders of such debt securities to institute a proceeding with respect to such indenture, subject
to certain conditions, which will be specified in the applicable prospectus supplement and which
may include, that the holders of at least a majority in aggregate principal amount of the debt
securities of such series then outstanding make a written request upon the trustee to exercise its
power under the indenture, indemnify the trustee and afford the trustee reasonable opportunity to
act. Even so, such holders may have an absolute right to receipt of the principal of, premium or
make-whole amount, if any, and interest when due, to require conversion or exchange of debt
securities if such indenture provides for convertibility or exchangeability at the option of the
holder and to institute suit for the enforcement of such rights. Any terms and provisions relating
to the foregoing types of provisions will be described in further detail in the applicable
prospectus supplement.
Modification of the Indenture
We and the trustee may modify any indenture that governs our debt securities of any series
covered by this prospectus with or without the consent of the holders of such debt securities,
under certain circumstances to be described in a prospectus supplement.
Defeasance; Satisfaction and Discharge
The prospectus supplement will outline the conditions under which we may elect to have certain
of our obligations under the indenture discharged and under which the indenture obligations will be
deemed to be satisfied.
Regarding the Trustee
We will identify the trustee and any relationship that we may have with such trustee, with
respect to any series of debt securities, in the prospectus supplement relating to the applicable
debt securities. You should note that if the trustee becomes a creditor of Amicus, the indenture
and the Trust Indenture Act of 1939 limit the rights of the trustee to obtain payment of claims in
certain cases, or to realize on certain property received in respect of any such claim, as security
or otherwise. The trustee and its affiliates may engage in, and will be permitted to continue to
engage in, other transactions with us and our affiliates. If, however, the trustee acquires any
conflicting interest within the meaning of the Trust Indenture Act of 1939, it must eliminate
such conflict or resign.
Governing Law
The law governing the indenture and the debt securities will be identified in the prospectus
supplement relating to the applicable indenture and debt securities.
-17-
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and current reports, proxy statements and other information with the
SEC. You may read and copy information filed by us with the SEC at the SECs public reference
section, 100 F Street, N.E., Washington, D.C. 20549. Information regarding the operation of the
public reference section can be obtained by calling 1-800-SEC-0330. The SEC also maintains an
Internet site at http://www.sec.gov that contains reports, statements and other information about
issuers, such as us, who file electronically with the SEC. We maintain an Internet site at
http://www.amicustherapeutics.com. However, the information on our Internet site is not
incorporated by reference in this prospectus and any prospectus supplement and you should not
consider it a part of this prospectus or any accompanying prospectus supplement.
The SEC allows us to incorporate by reference into this prospectus the information in other
documents that we file with it. This means that we can disclose important information to you by
referring you to those documents. The information incorporated by reference is considered to be a
part of this prospectus, and information in documents that we file later with the SEC will
automatically update and supersede information contained in documents filed earlier with the SEC or
contained in this prospectus. We incorporate by reference in this prospectus the documents listed
below and any future filings that we may make with the SEC under Sections 13(a), 13(c), 14, or
15(d) of the Securities Exchange Act of 1934, as amended, prior to the termination of the offering
under this prospectus; provided, however, that we are not incorporating, in each case, any
documents or information deemed to have been furnished and not filed in accordance with SEC rules:
|
|
|
Our Annual Report on Form 10-K for the year ended December 31, 2008 (File No.
001-33497); |
|
|
|
|
Our Current Reports on Form 8-K filed on January 8, 2009, February 18, 2009 and
February 27, 2009 (excluding any information furnished in such reports under exhibit 99.1
thereto); and |
|
|
|
|
The description of our common stock contained in our registration statement on Form
8-A (File No. 001-33497) filed May 23, 2007, under the Exchange Act, including any
amendment or report filed for the purpose of updating such description. |
You may obtain a copy of any or all of the documents referred to above which may have been or
may be incorporated by reference into this prospectus, except for exhibits to those documents
(unless the exhibits are specifically incorporated by reference into those documents) at no cost to
you by writing or telephoning us at the following address: Office of the Corporate Secretary,
Amicus Therapeutics, Inc., 6 Cedar Brook Drive, Cranbury, NJ 08512, telephone (609)-662-2000.
LEGAL MATTERS
The validity of the issuance of the securities offered hereby will be passed upon for us by
Bingham McCutchen LLP, Boston, Massachusetts. As appropriate, legal counsel representing the
selling stockholders, underwriters, dealers or agents will be named in the accompanying prospectus
supplement and may opine to certain legal matters.
EXPERTS
Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated
financial statements included in our Annual Report on Form 10-K for the year ended December 31,
2008, as set forth in their report, which is incorporated by reference in the prospectus and
elsewhere in this registration statement. Our consolidated financial statements are incorporated by
reference in reliance on Ernst & Young LLPs report, given on their authority as experts in
accounting and auditing.
-18-
PART II
INFORMATION NOT REQUIRED IN THE PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
Set forth below is an estimate (except in the case of the registration fee) of the amount of
fees and expenses to be incurred in connection with the issuance and distribution of the offered
securities registered hereby, other than underwriting discounts and commission, if any, incurred in
connection with the sale of the offered securities. All such amounts will be borne by Amicus
Therapeutics, Inc.
|
|
|
|
|
SEC Registration Fee |
|
$ |
5,580 |
|
Legal Fees and Expenses |
|
$ |
150,000 |
|
Accounting Fees and Expenses |
|
$ |
25,000 |
|
Blue Sky Fees and Expenses |
|
$ |
20,000 |
|
Printing Expenses |
|
$ |
10,000 |
|
Miscellaneous Fees and Expenses |
|
$ |
15,000 |
|
|
|
|
|
Total: |
|
$ |
225,580 |
|
|
|
|
|
Item 15. Indemnification of Directors and Officers.
Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the
personal liability of directors of a corporation to the corporation or its stockholders for
monetary damages for a breach of fiduciary duty as a director, except where the director breached
his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or
knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in
violation of Delaware corporate law or obtained an improper personal benefit. The Registrants
restated certificate of incorporation provides that no director of the Registrant shall be
personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty
as director, notwithstanding any provision of law imposing such liability, except to the extent
that the Delaware General Corporation Law prohibits the elimination or limitation of liability of
directors for breaches of fiduciary duty.
Section 145 of the Delaware General Corporation Law provides that a corporation has the power
to indemnify any person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative, by reason of the fact that the person is or was a director,
officer, employee or agent of the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses (including attorneys fees), judgments, fines
and amounts paid in settlements actually and reasonably incurred by the person in connection with
an action, suit or proceeding to which he or she is or is threatened to be made a party by reason
of such position, if such person acted in good faith and in a manner he or she reasonably believed
to be in or not opposed to the best interests of the corporation, and, in any criminal action or
proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the
case of actions brought by or in the right of the corporation, no indemnification shall be made
with respect to any claim, issue or matter as to which such person shall have been adjudged to be
liable to the corporation unless and only to the extent that the Delaware Court of Chancery or
other adjudicating court determines that, despite the adjudication of liability but in view of all
of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for
such expenses which the Delaware Court of Chancery or such other court shall deem proper.
The Registrants restated certificate of incorporation provides that the Registrant will, to
the fullest extent permitted by Section 145 of the Delaware General Corporation Law and the
Registrants by-laws (each as amended from time to time), indemnify each person who was or is a
party or is threatened to be made a party to any threatened, pending or completed action, suit or
proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he
or she is or was, or has agreed to become, a director or officer of the Registrant, or is or was
serving, or has agreed to serve, at the request of the Registrant, as a director, officer, partner,
or trustee of, or in a similar capacity with, another corporation, partnership, joint venture,
trust or other enterprise, including any employee benefit plan (all such persons being referred to
hereafter as an Indemnitee), or by reason of any action alleged to have been taken or omitted in
such capacity, against all expenses (including attorneys fees), judgments, fines and amounts paid
in settlement actually and reasonably incurred by, or on behalf of, the Indemnitee in connection
with such action, suit or proceeding and any appeal therefrom. Such indemnification may include
payment by the Registrant of expenses in defending an action or proceeding in advance of the final
disposition of such action or proceeding upon receipt of an undertaking by the Indemnitee (such
undertaking acceptable by the Registrant without reference to the financial ability of the
Indemnitee) to repay such payment if it is ultimately determined that the Indemnitee is not
entitled to indemnification under the Registrants restated certificate of incorporation; however,
the Registrant will not indemnify any person seeking indemnification in connection with a
proceeding (or part thereof) initiated by such person, unless such initiation was approved by the
Registrants board of directors. Also, the indemnification rights provided in the Registrants
restated certificate of incorporation (i) are not exclusive of any other rights to which those
indemnified may be
II-1
entitled under any law, agreement or vote of stockholders or disinterested directors or
otherwise, and (ii) will inure to the benefit of the heirs, executors and administrators of such
persons. The Registrant may, to the extent authorized from time to time by its board of directors,
grant indemnification rights to other employees of the Registrant or other persons serving the
Registrant and such rights may be equivalent to, or greater or less than, those set forth in the
Registrants restated certificate of incorporation.
The Registrant has entered into indemnification agreements with each of its directors. These
agreements, among other things, require the Registrant to indemnify each director to the fullest
extent permitted by Delaware law, including indemnification of expenses such as attorneys fees,
judgments, fines and settlement amounts incurred by the director in any action or proceeding,
including any action or proceeding by or in right of the Registrant, arising out of the persons
services as a director.
The Registrant maintains a general liability insurance policy that covers certain liabilities
of the Registrants directors and officers arising out of claims based on acts or omissions in
their capacities as directors or officers.
In any underwriting agreement that the Registrant enters into in connection with the sale of
common stock being registered hereby, the underwriters will agree to indemnify, under certain
conditions, the Registrant, its directors, its officers and persons who control the Registrant
within the meaning of the Securities Act, against certain liabilities.
II-2
Item 16. Exhibits
|
|
|
Exhibit |
|
Description |
|
|
|
1.1*
|
|
Form of underwriting / agency agreement |
|
|
|
4.1
|
|
Restated Certificate of Incorporation of the registrant
(incorporated by reference to Exhibit 3.2 of the registrants
Registration Statement on Form S-1 (Registration No. 333-141700),
as amended, originally filed with the SEC on May 17, 2007) |
|
|
|
4.2*
|
|
Certificate of Designations |
|
|
|
4.3
|
|
Restated By-laws of the of the registrant (incorporated by
reference to Exhibit 3.4 of the registrants Registration
Statement on Form S-1/A (Registration No. 333-141700), as
amended, originally filed with the SEC on April 27, 2007) |
|
|
|
4.4
|
|
Specimen Stock Certificate evidencing shares of common stock
(incorporated by reference to Exhibit 4.1 of the registrants
Registration Statement on Form S-1 (Registration No. 333-141700),
as amended, originally filed with the SEC on March 30, 2007) |
|
|
|
4.5*
|
|
Specimen Stock Certificate evidencing shares of preferred stock |
|
|
|
4.6
|
|
Third Amended and Restated Investor Rights Agreement, dated as of
September 13, 2006, as amended, by and among the registrant and
certain stockholders of the registrant (incorporated by reference
to Exhibit 4.3 of the registrants Registration Statement on Form
S-1 (Registration No. 333-141700), as amended, originally filed
with the SEC on March 30, 2007) |
|
|
|
4.7*
|
|
Form of Common Stock Warrant Agreement and Warrant Certificate |
|
|
|
4.8*
|
|
Form of Preferred Stock Warrant Agreement and Warrant Certificate |
|
|
|
4.9*
|
|
Form of Debt Securities Warrant Agreement and Warrant Certificate |
|
|
|
4.10
|
|
Form of Indenture (filed herewith) |
|
|
|
5.1
|
|
Opinion of Bingham McCutchen LLP (filed herewith) |
|
|
|
12.1
|
|
Statement re: Computation of Ratios (filed herewith) |
|
|
|
23.1
|
|
Consent of Bingham McCutchen LLP (included in Exhibit 5.1) |
|
|
|
23.2
|
|
Consent of Ernst & Young LLP (filed herewith) |
|
|
|
24.1
|
|
Power of attorneyincluded on the signature page |
|
|
|
25.1
|
|
Statement of Eligibility of Trustee Under Debt Indenture (to be
filed separately pursuant to Section 305(b)(2) of the Trust
Indenture Act of 1939) |
|
|
|
* |
|
To be filed, if necessary, subsequent to the effectiveness of this
registration statement by an amendment to this registration statement
or incorporated by reference pursuant to a Current Report on Form 8-K
in connection with an offering of securities. |
II-3
Item 17. Undertakings.
(a) The undersigned Registrant hereby undertakes:
(1) to file, during any period in which offers or sales are being made, a post-effective
amendment to this Registration Statement: (i) to include any prospectus required by
Section 10(a)(3) of the Securities Act; (ii) to reflect in the prospectus any facts or events
arising after the effective date of the Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the
information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total dollar value of securities offered would not
exceed that which was registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed with the Commission
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more
than a 20% change in the maximum aggregate offering price set forth in the Calculation of
Registration Fee table in the effective registration statement; and (iii) to include any material
information with respect to the plan of distribution not previously disclosed in the Registration
Statement or any material change to such information in the Registration Statement; provided,
however , that paragraphs (i), (ii) and (iii) do not apply if the Registration Statement is on
Form S-3 and the information required to be included in a post-effective amendment by those
paragraphs is contained in reports filed with or furnished to the Commission by the Registrant
pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are
incorporated by reference in the Registration Statement, or is contained in a form of prospectus
filed pursuant to Rule 424(b) that is part of the registration statement;
(2) that, for the purpose of determining any liability under the Securities Act of 1933, each
such post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof;
(3) to remove from registration by means of a post-effective amendment any of the securities
being registered which remain unsold at the termination of the offering;
(4) that, for the purpose of determining liability under the Securities Act of 1933 to any
purchaser:
(A) Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be
part of the registration statement as of the date the filed prospectus was deemed part of and
included in the registration statement; and
(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part
of a registration statement in reliance on Rule 430B relating to an offering made pursuant to
Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by
Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the
registration statement as of the earlier of the date such form of prospectus is first used after
effectiveness or the date of the first contract of sale of securities in the offering described in
prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is
at that date an underwriter, such date shall be deemed to be a new effective date of the
registration statement relating to the securities in the registration statement to which the
prospectus relates, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof. Provided, however , that no statement made in a
registration statement or prospectus that is part of the registration statement or made in a
document incorporated or deemed incorporated by reference into the registration statement or
prospectus that is part of the registration statement will, as to a purchaser with a time of
contract of sale prior to such effective date, supersede or modify any statement that was made in
the registration statement or prospectus that was part of the registration statement or made in any
such document immediately prior to such effective date; and
(5) that, for the purpose of determining liability of the Registrant under the Securities Act
of 1933 to any purchaser in the initial distribution of the securities, the undersigned Registrant
undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this
registration statement, regardless of the underwriting method used to sell the securities to the
purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned Registrant will be a seller to the purchaser and will be considered
to offer or sell such securities to such purchaser:
(i) Any preliminary prospectus or prospectus of the undersigned Registrant relating to the
offering required to be filed pursuant to Rule 424;
(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the
undersigned Registrant or used or referred to by the undersigned Registrant;
(iii) The portion of any other free writing prospectus relating to the offering containing
material information about the undersigned Registrant or its securities provided by or on behalf of
an undersigned Registrant; and
II-4
(iv) Any other communication that is an offer in the offering made by the undersigned
Registrant to the purchaser.
(b) The undersigned Registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act, each filing of Registrants annual report pursuant to
Section 13(a) or Section 15(d) of the Securities Exchange Act that is incorporated by reference in
this Registration Statement shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(c) The undersigned registrant hereby undertakes that: (i) for purposes of determining any
liability under the Securities Act of 1933, the information omitted from the form of prospectus
filed as part of the registration statement in reliance upon Rule 430A and contained in the form of
prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities
Act shall be deemed to be part of the registration statement as of the time it was declared
effective; and (ii) for the purpose of determining any liability under the Securities Act, each
post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.
(d) If and when applicable, the undersigned Registrant hereby undertakes to file an
application for the purpose of determining the eligibility of the trustee to act under subsection
(a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations
prescribed by the Securities and Exchange Commission under Section 305(b)(2) of the Act.
(e) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be
permitted to directors, officers and controlling persons of the registrant pursuant to the
provisions described under Item 15 above, or otherwise, the registrant has been advised that in the
opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such indemnification by it is against public policy
as expressed in the Act and will be governed by the final adjudication of such issue.
II-5
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant, Amicus
Therapeutics, certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on
its behalf by the undersigned, thereunto duly authorized, in the in the city of Cranbury, New
Jersey, on the 3rd day of April, 2009.
|
|
|
|
|
|
|
|
|
AMICUS THERAPEUTICS, INC |
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ John F. Crowley
John F. Crowley
|
|
|
|
|
|
|
President and Chief Executive Officer |
|
|
We, the undersigned officers and directors of Amicus Therapeutics, Inc., hereby severally
constitute and appoint James E. Dentzer, Matthew R. Patterson and Geoffrey P. Gilmore, and all or
any one of them, our true and lawful attorneys-in-fact and agents, with full power of substitution
and re-substitution in for him and in his name, place and stead, and in any and all capacities, to
sign any and all amendments (including post-effective amendments) to this Registration Statement,
and any subsequent registration statements pursuant to Rule 462 of the Securities Act, and to file
the same, with all exhibits thereto and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of
them, full power and authority to do and perform each and every act and thing requisite and
necessary to be done in and about the premises, as fully to all intents and purposes as he might or
could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact or his
substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by
the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
/s/ John F. Crowley
(John F. Crowley)
|
|
Chief Executive Officer
(Principal Executive Officer)
|
|
April 3, 2009 |
|
|
|
|
|
/s/ James E. Dentzer
(James E. Dentzer)
|
|
Chief Financial Officer
(Principal Financial and
Accounting Officer)
|
|
April 3, 2009 |
|
|
|
|
|
/s/ Donald J. Hayden
(Donald J. Hayden)
|
|
Chairman of the Board
|
|
April 3, 2009 |
|
|
|
|
|
/s/ Alexander E. Barkas, Ph.D.
(Alexander E. Barkas, Ph.D.)
|
|
Director
|
|
April 3, 2009 |
|
|
|
|
|
/s/ Michael G. Raab
(Michael G. Raab)
|
|
Director
|
|
April 3, 2009 |
|
|
|
|
|
/s/ Glenn Sblendorio
(Glenn Sblendorio)
|
|
Director
|
|
April 3, 2009 |
|
|
/s/ James N. Topper, M.D., Ph.D.
(James N. Topper, M.D., Ph.D.)
|
|
Director
|
|
April 3, 2009 |
|
|
|
|
|
/s/ Sol J. Barer, Ph.D.
(Sol J. Barer, Ph.D.)
|
|
Director
|
|
April 3, 2009 |
EXHIBIT INDEX
|
|
|
Exhibit |
|
Description |
|
|
|
1.1*
|
|
Form of underwriting / agency agreement |
|
|
|
4.1
|
|
Restated Certificate of Incorporation of the registrant
(incorporated by reference to Exhibit 3.2 of the registrants
Registration Statement on Form S-1 (Registration No. 333-141700),
as amended, originally filed with the SEC on May 17, 2007) |
|
|
|
4.2*
|
|
Certificate of Designations |
|
|
|
4.3
|
|
Restated By-laws of the of the registrant (incorporated by
reference to Exhibit 3.4 of the registrants Registration
Statement on Form S-1/A (Registration No. 333-141700), as
amended, originally filed with the SEC on April 27, 2007) |
|
|
|
4.4
|
|
Specimen Stock Certificate evidencing shares of common stock
(incorporated by reference to Exhibit 4.1 of the registrants
Registration Statement on Form S-1 (Registration No. 333-141700),
as amended, originally filed with the SEC on March 30, 2007) |
|
|
|
4.5*
|
|
Specimen Stock Certificate evidencing shares of preferred stock |
|
|
|
4.6
|
|
Third Amended and Restated Investor Rights Agreement, dated as of
September 13, 2006, as amended, by and among the registrant and
certain stockholders of the registrant (incorporated by reference
to Exhibit 4.3 of the registrants Registration Statement on Form
S-1 (Registration No. 333-141700), as amended, originally filed
with the SEC on March 30, 2007) |
|
|
|
4.7*
|
|
Form of Common Stock Warrant Agreement and Warrant Certificate |
|
|
|
4.8*
|
|
Form of Preferred Stock Warrant Agreement and Warrant Certificate |
|
|
|
4.9*
|
|
Form of Debt Securities Warrant Agreement and Warrant Certificate |
|
|
|
4.10
|
|
Form of Indenture (filed herewith) |
|
|
|
5.1
|
|
Opinion of Bingham McCutchen LLP (filed herewith) |
|
|
|
12.1
|
|
Statement re: Computation of Ratios (filed herewith) |
|
|
|
23.1
|
|
Consent of Bingham McCutchen LLP (included in Exhibit 5.1) |
|
|
|
23.2
|
|
Consent of Ernst & Young LLP (filed herewith) |
|
|
|
24.1
|
|
Power of attorneyincluded on the signature page |
|
|
|
25.1
|
|
Statement of Eligibility of Trustee Under Debt Indenture (to be
filed separately pursuant to Section 305(b)(2) of the Trust
Indenture Act of 1939) |
|
|
|
* |
|
To be filed, if necessary, subsequent to the effectiveness of this
registration statement by an amendment to this registration statement
or incorporated by reference pursuant to a Current Report on Form 8-K
in connection with an offering of securities. |
EX-4.10
Exhibit 4.10
AMICUS THERAPEUTICS, INC.
and
, as Trustee
INDENTURE
Dated as of ,
TABLE OF CONTENTS
|
|
|
|
|
|
|
Page |
|
|
|
|
|
|
ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE |
|
|
1 |
|
1.1. DEFINITIONS |
|
|
1 |
|
1.2. OTHER DEFINITIONS |
|
|
5 |
|
1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT |
|
|
6 |
|
1.4. RULES OF CONSTRUCTION |
|
|
6 |
|
|
|
|
|
|
ARTICLE 2 THE SECURITIES |
|
|
7 |
|
2.1. ISSUABLE IN SERIES |
|
|
7 |
|
2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES |
|
|
7 |
|
2.3. EXECUTION AND AUTHENTICATION |
|
|
9 |
|
2.4. REGISTRAR AND PAYING AGENT |
|
|
10 |
|
2.5. PAYING AGENT TO HOLD ASSETS IN TRUST |
|
|
11 |
|
2.6. SECURITYHOLDER LISTS |
|
|
12 |
|
2.7. TRANSFER AND EXCHANGE |
|
|
12 |
|
2.8. REPLACEMENT SECURITIES |
|
|
13 |
|
2.9. OUTSTANDING SECURITIES |
|
|
13 |
|
2.10. WHEN TREASURY SECURITIES DISREGARDED; DETERMINATION OF HOLDERS ACTION |
|
|
13 |
|
2.11. TEMPORARY SECURITIES |
|
|
14 |
|
2.12. CANCELLATION |
|
|
14 |
|
2.13. PAYMENT OF INTEREST; DEFAULTED INTEREST; COMPUTATION OF INTEREST |
|
|
14 |
|
2.14. CUSIP NUMBER |
|
|
15 |
|
2.15. PROVISIONS FOR GLOBAL SECURITIES |
|
|
15 |
|
2.16. PERSONS DEEMED OWNERS |
|
|
16 |
|
|
|
|
|
|
ARTICLE 3 REDEMPTION |
|
|
17 |
|
3.1. NOTICES TO TRUSTEE |
|
|
17 |
|
3.2. SELECTION BY TRUSTEE OF SECURITIES TO BE REDEEMED |
|
|
17 |
|
3.3. NOTICE OF REDEMPTION |
|
|
17 |
|
3.4. EFFECT OF NOTICE OF REDEMPTION |
|
|
18 |
|
3.5. DEPOSIT OF REDEMPTION PRICE |
|
|
19 |
|
3.6. SECURITIES REDEEMED IN PART |
|
|
19 |
|
-i-
TABLE OF CONTENTS
(continued)
|
|
|
|
|
|
|
Page |
|
|
|
|
|
|
ARTICLE 4 COVENANTS |
|
|
19 |
|
4.1. PAYMENT OF SECURITIES |
|
|
19 |
|
4.2. SEC REPORTS |
|
|
19 |
|
4.3. WAIVER OF STAY, EXTENSION OR USURY LAWS |
|
|
20 |
|
4.4. COMPLIANCE CERTIFICATE |
|
|
20 |
|
4.5. CORPORATE EXISTENCE |
|
|
21 |
|
|
|
|
|
|
ARTICLE 5 SUCCESSOR CORPORATION |
|
|
21 |
|
5.1. LIMITATION ON CONSOLIDATION, MERGER AND SALE OF ASSETS |
|
|
21 |
|
5.2. SUCCESSOR PERSON SUBSTITUTED |
|
|
22 |
|
|
|
|
|
|
ARTICLE 6 DEFAULTS AND REMEDIES |
|
|
22 |
|
6.1. EVENTS OF DEFAULT |
|
|
22 |
|
6.2. ACCELERATION |
|
|
23 |
|
6.3. REMEDIES |
|
|
24 |
|
6.4. WAIVER OF PAST DEFAULTS AND EVENTS OF DEFAULT |
|
|
24 |
|
6.5. CONTROL BY MAJORITY |
|
|
24 |
|
6.6. LIMITATION ON SUITS |
|
|
25 |
|
6.7. RIGHTS OF HOLDERS TO RECEIVE PAYMENT |
|
|
25 |
|
6.8. COLLECTION SUIT BY TRUSTEE |
|
|
25 |
|
6.9. TRUSTEE MAY FILE PROOFS OF CLAIM |
|
|
26 |
|
6.10. PRIORITIES |
|
|
26 |
|
6.11. UNDERTAKING FOR COSTS |
|
|
26 |
|
|
|
|
|
|
ARTICLE 7 TRUSTEE |
|
|
27 |
|
7.1. DUTIES OF TRUSTEE |
|
|
27 |
|
7.2. RIGHTS OF TRUSTEE |
|
|
28 |
|
7.3. INDIVIDUAL RIGHTS OF TRUSTEE |
|
|
29 |
|
7.4. TRUSTEES DISCLAIMER |
|
|
29 |
|
7.5. NOTICE OF DEFAULT |
|
|
29 |
|
7.6. REPORTS BY TRUSTEE TO HOLDERS |
|
|
30 |
|
7.7. COMPENSATION AND INDEMNITY |
|
|
30 |
|
-ii-
TABLE OF CONTENTS
(continued)
|
|
|
|
|
|
|
Page |
|
|
|
|
|
|
7.8. REPLACEMENT OF TRUSTEE |
|
|
31 |
|
7.9. SUCCESSOR TRUSTEE BY CONSOLIDATION, MERGER OR CONVERSION |
|
|
32 |
|
7.10. ELIGIBILITY; DISQUALIFICATION |
|
|
32 |
|
7.11. PREFERENTIAL COLLECTION OF CLAIMS AGAINST COMPANY |
|
|
32 |
|
7.12. PAYING AGENTS |
|
|
32 |
|
|
|
|
|
|
ARTICLE 8 AMENDMENTS, SUPPLEMENTS AND WAIVERS |
|
|
33 |
|
8.1. WITHOUT CONSENT OF HOLDERS |
|
|
33 |
|
8.2. WITH CONSENT OF HOLDERS |
|
|
33 |
|
8.3. COMPLIANCE WITH TRUST INDENTURE ACT |
|
|
35 |
|
8.4. REVOCATION AND EFFECT OF CONSENTS |
|
|
35 |
|
8.5. NOTATION ON OR EXCHANGE OF SECURITIES |
|
|
35 |
|
8.6. TRUSTEE TO SIGN AMENDMENTS, ETC |
|
|
36 |
|
|
|
|
|
|
ARTICLE 9 DISCHARGE OF INDENTURE; DEFEASANCE |
|
|
36 |
|
9.1. DISCHARGE OF INDENTURE |
|
|
36 |
|
9.2. LEGAL DEFEASANCE |
|
|
36 |
|
9.3. COVENANT DEFEASANCE |
|
|
37 |
|
9.4. CONDITIONS TO LEGAL DEFEASANCE OR COVENANT DEFEASANCE |
|
|
37 |
|
9.5. DEPOSITED MONEY AND U.S. AND FOREIGN GOVERNMENT OBLIGATIONS TO BE HELD
IN TRUST; OTHER MISCELLANEOUS PROVISIONS |
|
|
39 |
|
9.6. REINSTATEMENT |
|
|
39 |
|
9.7. MONEYS HELD BY PAYING AGENT |
|
|
39 |
|
9.8. MONEYS HELD BY TRUSTEE |
|
|
40 |
|
|
|
|
|
|
ARTICLE 10 MISCELLANEOUS |
|
|
40 |
|
10.1. TRUST INDENTURE ACT CONTROLS |
|
|
40 |
|
10.2. NOTICES |
|
|
40 |
|
10.3. COMMUNICATIONS BY HOLDERS WITH OTHER HOLDERS |
|
|
42 |
|
10.4. CERTIFICATE AND OPINION AS TO CONDITIONS PRECEDENT |
|
|
42 |
|
10.5. STATEMENT REQUIRED IN CERTIFICATE AND OPINION |
|
|
42 |
|
-iii-
TABLE OF CONTENTS
(continued)
|
|
|
|
|
|
|
Page |
|
|
|
|
|
|
10.6. RULES BY TRUSTEE AND AGENTS |
|
|
42 |
|
10.7. BUSINESS DAYS; LEGAL HOLIDAYS; PLACE OF PAYMENT |
|
|
43 |
|
10.8. GOVERNING LAW |
|
|
43 |
|
10.9. NO ADVERSE INTERPRETATION OF OTHER AGREEMENTS |
|
|
43 |
|
10.10. SUCCESSORS |
|
|
43 |
|
10.11. MULTIPLE COUNTERPARTS |
|
|
43 |
|
10.12. TABLE OF CONTENTS, HEADINGS, ETC |
|
|
44 |
|
10.13. SEVERABILITY |
|
|
44 |
|
10.14. SECURITIES IN A FOREIGN CURRENCY OR IN EUROS |
|
|
44 |
|
10.15. JUDGMENT CURRENCY |
|
|
45 |
|
-iv-
CROSS-REFERENCE TABLE
|
|
|
TIA SECTION |
|
INDENTURE SECTION |
310(a)(1)(2)(5)
|
|
7.10 |
310(a)(3)(4)
|
|
Inapplicable |
310(b)
|
|
7.8; 7.10 |
310(c)
|
|
Inapplicable |
311(a)(b)
|
|
7.11 |
311(c)
|
|
Inapplicable |
312(a)
|
|
2.6 |
312(b)(c)
|
|
10.3 |
313(a)(b)
|
|
7.6 |
313(c)
|
|
7.6; 10.2 |
313(d)
|
|
7.6 |
314(a)
|
|
4.2; 4.4; 10.2 |
314(b)
|
|
N/A |
314(c)(1)(2)
|
|
10.4; 10.5 |
314(c)(3)
|
|
Inapplicable |
314(d)
|
|
Inapplicable |
314(e)
|
|
10.5 |
314(f)
|
|
Inapplicable |
315(a)
|
|
7.1, 7.2 |
315(b)
|
|
7.5; 10.2 |
315(c)
|
|
7.1 |
315(d)
|
|
7.1; 7.2 |
315(e)
|
|
6.11 |
316(a)(last sentence)
|
|
2.10 |
316(a)(1)(A)
|
|
6.5 |
316(a)(1)(B)
|
|
6.4 |
316(a)(2)
|
|
8.2 |
316(b)
|
|
6.7 |
316(c)
|
|
8.4 |
317(a)(1)
|
|
6.8 |
317(a)(2)
|
|
6.9 |
317(b)
|
|
2.5; 7.12 |
318(a)
|
|
10.1 |
Note: This Cross-Reference Table shall not, for any purpose, be deemed to be a part of the
Indenture.
-v-
INDENTURE, dated as of
,
, by and between Amicus Therapeutics,
Inc., a Delaware corporation, as Issuer (the Company) and
, a
organized under the laws of
, as Trustee (the
Trustee).
RECITALS OF THE COMPANY
The Company has duly authorized the execution and delivery of this Indenture to provide for
the issuance from time to time of its debentures, notes or other evidences of indebtedness to be
issued in one or more series (the Securities), as herein provided, up to such principal amount as
may from time to time be authorized in or pursuant to one or more resolutions of the Board of
Directors or by supplemental indenture.
All things necessary to make this Indenture a valid agreement of the Company in accordance
with its terms have been done, and the execution and delivery thereof have been in all respects
duly authorized by the parties hereto.
NOW, THEREFORE, THIS INDENTURE WITNESSETH:
For and in consideration of the premises and the purchase of the Securities by the Holders
thereof, it is mutually agreed, for the equal and proportionate benefit of all Holders of the
Securities of a Series thereof, as follows:
ARTICLE 1
DEFINITIONS AND INCORPORATION BY REFERENCE
1.1. DEFINITIONS.
Affiliate of any specified Person means any other Person which, directly or indirectly
through one or more intermediaries, controls, or is controlled by or is under common control with,
such specified Person. For the purposes of this definition, control (including, with correlative
meanings, the terms controlling, controlled by and under common control with), as used with
respect to any Person, means the possession, directly or indirectly, of the power to direct or
cause the direction of the management or policies of such Person, whether through the ownership of
voting securities, by agreement or otherwise.
Agent means any Registrar, Paying Agent, co-registrar or agent for service of notices and
demands.
Board of Directors means the Board of Directors of the Company or any committee duly
authorized to act therefor.
Board Resolution means a copy of a resolution certified pursuant to an Officers Certificate
to have been duly adopted by the Board of Directors of the Company and to be in full force and
effect on the date of such certification which has been delivered to the Trustee.
Capital Stock means, with respect to any Person, any and all shares or other equivalents
(however designated) of capital stock, partnership interests or any other participation, right or
other interest in the nature of an equity interest in such Person or any option, warrant or other
security convertible into any of the foregoing.
Company means the party named as such in the first paragraph of this Indenture until a
successor replaces such party pursuant to Article 5 of this Indenture, and thereafter means the
successor and any other primary obligor on the Securities.
Company Order means a written order signed in the name of the Company by two of the
Companys executive Officers, one of whom must be its Chief Executive Officer or its Chief
Financial Officer.
Company Request means any written request signed in the name of the Company by its Chief
Executive Officer, its President, any Vice President, its Chief Financial Officer or its Treasurer
and attested to by its Secretary or any Assistant Secretary.
Corporate Trust Office means the office of the Trustee at which at any particular time its
corporate trust business shall be principally administered.
Default means any event that is, or that with the passing of time or giving of notice or
both would be, an Event of Default.
Depository means, with respect to the Securities of any Series issuable or issued in whole
or in part in the form of one or more Global Securities, the Person designated as Depository for
such Series by the Company, which Depository shall be a clearing agency registered under the
Exchange Act, until a successor Depository shall have become such pursuant to the applicable
provisions of this Indenture, and thereafter Depository shall mean each Person who is then a
Depository hereunder, and if at any time there is more than one such Person, such Persons.
Dollars means the currency of the United States of America.
Euro means the single currency of participating member states of the economic and monetary
union as contemplated in the Treaty on European Union.
Exchange Act means the Securities Exchange Act of 1934, as amended.
Foreign Currency means any currency or currency unit issued by a government other than the
government of the United States of America.
Foreign Government Obligations means, with respect to Securities that are denominated in a
Foreign Currency, (i) direct obligations of the government that issued or caused to be issued such
currency for the payment of which obligations its full faith and credit is pledged or (ii)
obligations of a Person controlled or supervised by, or acting as an agency or instrumentality of,
such government, the timely payment of which is unconditionally guaranteed as a full faith and
credit obligation by such government, which, in either case under clauses (i) and (ii), are not
callable or redeemable at the option of the issuer thereof.
-2-
GAAP means generally accepted accounting principles consistently applied as in effect in the
United States of America from time to time.
Global Security or Global Securities means a Security or Securities, as the case may be,
in the form established pursuant to Section 2.2, evidencing all or part of a Series of Securities
issued to the Depository for such Series or its nominee, and registered in the name of such
Depository or nominee, and bearing the legend set forth in Section 2.15(c) (or such other legend(s)
as may be applied to such Securities in accordance with Section 2.2(24)).
Holder or Securityholder means the Person in whose name a Security is registered on the
Registrars books.
Indebtedness means (without duplication), with respect to any Person, any indebtedness at
any time outstanding, secured or unsecured, contingent or otherwise, which is for borrowed money
(whether or not the recourse of the lender is to the whole of the assets of such Person or only to
a portion thereof), or evidenced by bonds, notes, debentures or similar instruments, or
representing the balance deferred and unpaid of the purchase price of any property (excluding any
balances that constitute accounts payable or trade payables, and other accrued liabilities arising
in the ordinary course of business), if and to the extent any of the foregoing indebtedness would
appear as a liability upon a balance sheet of such Person prepared in accordance with GAAP.
Indenture means this Indenture as amended, restated or supplemented from time to time.
Interest Payment Date, when used with respect to any Security, means the Stated Maturity of
an installment of interest on such Security.
Lien means, with respect to any property or assets of any Person, any mortgage or deed of
trust, pledge, hypothecation, assignment, deposit arrangement, security interest, lien, charge,
easement, encumbrance, preference, priority or other security agreement or preferential arrangement
of any kind or nature whatsoever on or with respect to such property or assets (including, without
limitation, any capitalized lease obligation, conditional sales or other title retention agreement
having substantially the same economic effect as any of the foregoing).
Maturity, when used with respect to any Security, means the date on which the principal of
such Security, or an installment of principal, becomes due and payable as therein or herein
provided, whether at the Stated Maturity or by declaration of acceleration, call for redemption,
notice of option to elect payment or otherwise.
Officer means the Chief Executive Officer, the President, any Vice President, the Chief
Financial Officer, the Treasurer or the Secretary of the Company, or any other officer designated
by the Board of Directors, as the case may be.
Officers Certificate means, with respect to any Person, a certificate signed by the
Chairman, Chief Executive Officer, President or any Senior or Executive Vice President and the
Chief Financial Officer or any Treasurer of such Person, that shall comply with applicable
provisions of this Indenture.
-3-
Opinion of Counsel means a written opinion from legal counsel, which counsel is reasonably
acceptable to the Trustee. The counsel may be an employee of or counsel to the Company.
Person means any individual, corporation, limited liability company, partnership, joint
venture, association, joint-stock company, trust, unincorporated organization or government
(including any agency or political subdivision thereof).
Redemption Date, when used with respect to any Security to be redeemed, means the date fixed
for such redemption pursuant to this Indenture.
Responsible Officer, when used with respect to the Trustee, means any officer within the
corporate trust department or division of the Trustee (or any successor group of the Trustee) or
any other officer of the Trustee customarily performing functions similar to those performed by any
of the above designated officers, and also means, with respect to a particular corporate trust
matter, any other officer to whom such matter is referred because of his knowledge of and
familiarity with the particular subject.
SEC means the United States Securities and Exchange Commission as constituted from time to
time, or any successor performing substantially the same functions.
Securities means the securities that are issued under this Indenture, as amended or
supplemented from time to time pursuant to this Indenture.
Securities Act means the Securities Act of 1933, as amended.
Series or Series of Securities means each series of debentures, notes or other debt
instruments of the Company created pursuant to Sections 2.1 and 2.2.
Significant Subsidiary means (i) any direct or indirect Subsidiary of the Company that would
be a significant subsidiary as defined in Article 1, Rule 1-02 of Regulation S-X, promulgated
pursuant to the Securities Act, as such regulation is in effect on the date hereof, or (ii) any
group of direct or indirect Subsidiaries of the Company that, taken together as a group, would be a
significant subsidiary as defined in Article 1, Rule 1-02 of Regulation S-X, promulgated pursuant
to the Securities Act, as such regulation is in effect on the date hereof.
Stated Maturity, when used with respect to any Security or any installment of principal
thereof or interest thereon, means the date specified in such Security as the fixed date on which
the principal of such Security, or such installment of principal or interest, is due and payable,
and when used with respect to any other Indebtedness, means the date specified in the instrument
governing such Indebtedness as the fixed date on which the principal of such Indebtedness, or any
installment of interest thereon, is due and payable.
Subsidiary of any specified Person means any corporation, limited liability company,
partnership, joint venture, association or other business entity, whether now existing or hereafter
organized or acquired, (i) in the case of a corporation, of which more than 50% of the total voting
power of the Capital Stock entitled (without regard to the occurrence of any contingency) to vote
in the election of directors thereof is held, directly or indirectly, by such Person or any of
-4-
its Subsidiaries; or (ii) in the case of a partnership, joint venture, association or other
business entity, with respect to which such Person or any of its Subsidiaries has the power to
direct or cause the direction of the management and policies of such entity by contract or
otherwise, or if in accordance with GAAP such entity is consolidated with such Person for financial
statement purposes.
TIA means the Trust Indenture Act of 1939 (15 U.S. Code Section 77aaa-77bbbb) as in effect
on the date of this Indenture (except as provided in Section 8.3).
Trustee means the party named as such in this Indenture until a successor replaces it
pursuant to this Indenture, and thereafter means the successor, and if at any time there is more
than one such Person, Trustee as used with respect to the Securities of any Series shall mean the
Trustee with respect to Securities of that Series.
U.S. Government Obligations means direct non-callable obligations of, or non-callable
obligations guaranteed by, the United States of America for the payment of which obligation or
guarantee the full faith and credit of the United States of America is pledged.
1.2. OTHER DEFINITIONS.
The definitions of the following terms may be found in the sections indicated as follows:
|
|
|
TERM |
|
DEFINED IN SECTION |
Bankruptcy Law
|
|
6.1 |
Business Day
|
|
10.7 |
Covenant Defeasance
|
|
9.3 |
Custodian
|
|
6.1 |
Event of Default
|
|
6.1 |
Journal
|
|
10.15 |
Judgment Currency
|
|
10.16 |
Legal Defeasance
|
|
9.2 |
Legal Holiday
|
|
10.7 |
Market Exchange Rate
|
|
10.15 |
New York Paying Agent
|
|
2.4 |
Paying Agent
|
|
2.4 |
Place of Payment
|
|
10.7 |
Registrar
|
|
2.4 |
Required Currency
|
|
10.16 |
Service Agent
|
|
2.4 |
-5-
1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT.
Whenever this Indenture refers to a provision of the TIA, the portion of such provision
required to be incorporated herein in order for this Indenture to be qualified under the TIA is
incorporated by reference in and made a part of this Indenture. The following TIA terms used in
this Indenture have the following meanings:
Commission means the SEC.
indenture securities means the Securities.
indenture securityholder means a Holder or Securityholder.
indenture to be qualified means this Indenture.
indenture trustee or institutional trustee means the Trustee.
obligor on the indenture securities means the Company.
All other terms used in this Indenture that are defined by the TIA, defined in the TIA by
reference to another statute or defined by SEC rule have the meanings therein assigned to them.
1.4. RULES OF CONSTRUCTION.
Unless the context otherwise requires:
(1) a term has the meaning assigned to it herein, whether defined expressly or by
reference;
(2) an accounting term not otherwise defined has the meaning assigned to it in
accordance with GAAP;
(3) or is not exclusive;
(4) words in the singular include the plural, and in the plural include the singular;
(5) words used herein implying any gender shall apply to each gender; and
(6) the words herein, hereof and hereunder and other words of similar import
refer to this Indenture as a whole and not to any particular Article, Section or other
subdivision.
-6-
ARTICLE 2
THE SECURITIES
2.1. ISSUABLE IN SERIES.
The aggregate principal amount of Securities that may be authenticated and delivered under
this Indenture is $100,000,000. The Securities may be issued in one or more Series. All Securities
of a Series shall be identical except as may be set forth in a Board Resolution, a supplemental
indenture or an Officers Certificate detailing the adoption of the terms thereof pursuant to the
authority granted under a Board Resolution. In the case of Securities of a Series to be issued from
time to time, the Board Resolution, Officers Certificate or supplemental indenture may provide for
the method by which specified terms (such as interest rate, Stated Maturity, record date or date
from which interest shall accrue) are to be determined. Securities may differ between Series in
respect of any matters, PROVIDED, that all Series of Securities shall be equally and ratably
entitled to the benefits of the Indenture.
2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES.
At or prior to the issuance of any Securities within a Series, the following shall be
established (as to the Series generally, in the case of Subsection 2.2(1) and either as to such
Securities within the Series or as to the Series generally in the case of Subsections 2.2(2)
through 2.2(24)) by a Board Resolution, a supplemental indenture or an Officers Certificate, in
each case, pursuant to authority granted under a Board Resolution:
(1) the title of the Series (which shall distinguish the Securities of that particular
Series from the Securities of any other Series);
(2) any limit upon the aggregate principal amount of the Securities of the Series which
may be authenticated and delivered under this Indenture (except for Securities authenticated
and delivered upon registration of transfer of, or in exchange for, or in lieu of, other
Securities of the Series pursuant to Section 2.7, 2.8, 2.11, 3.6 or 8.5);
(3) the price or prices (expressed as a percentage of the principal amount thereof) at
which the Securities of the Series will be issued;
(4) the date or dates on which the principal of the Securities of the Series is
payable;
(5) the rate or rates (which may be fixed or variable) per annum or, if applicable, the
method used to determine such rate or rates (including, but not limited to, any commodity,
commodity index, stock exchange index or financial index) at which the Securities of the
Series shall bear interest, if any, the date or dates from which such interest, if any,
shall accrue, the date or dates on which such interest, if any, shall commence and be
payable and any regular record date for the interest payable on any Interest Payment Date;
-7-
(6) the place or places where the principal of, and interest and premium, if any, on,
the Securities of the Series shall be payable, or the method of such payment, if by wire
transfer, mail or other means;
(7) if applicable, the period or periods within which, the price or prices at which and
the terms and conditions upon which the Securities of the Series may be redeemed, in whole
or in part, at the option of the Company;
(8) the obligation, if any, of the Company to redeem or purchase the Securities of the
Series pursuant to any sinking fund or analogous provisions or at the option of a Holder
thereof, and the period or periods within which, the price or prices at which and the terms
and conditions upon which Securities of the Series shall be redeemed or purchased, in whole
or in part, pursuant to such obligation;
(9) the dates, if any, on which and the price or prices at which the Securities of the
Series will be repurchased by the Company at the option of the Holders thereof, and other
detailed terms and provisions of such repurchase obligations;
(10) if other than denominations of $1,000 and any integral multiple thereof, the
denominations in which the Securities of the Series shall be issuable;
(11) the forms of the Securities of the Series in bearer (if to be issued outside of
the United States of America) or fully registered form (and, if in fully registered form,
whether the Securities will be issuable as Global Securities);
(12) if other than the principal amount thereof, the portion of the principal amount of
the Securities of the Series that shall be payable upon declaration of acceleration of the
Maturity thereof pursuant to Section 6.2;
(13) the currency of denomination of the Securities of the Series, which may be Dollars
or any Foreign Currency, including, but not limited to, the Euro, and, if such currency of
denomination is a composite currency other than the Euro, the agency or organization, if
any, responsible for overseeing such composite currency;
(14) the designation of the currency, currencies or currency units in which payment of
the principal of, and interest and premium, if any, on, the Securities of the Series will be
made;
(15) if payments of principal of, or interest or premium, if any, on, the Securities of
the Series are to be made in one or more currencies or currency units other than that or
those in which such Securities are denominated, the manner in which the exchange rate with
respect to such payments will be determined;
(16) the manner in which the amounts of payment of principal of, or interest and
premium, if any, on, the Securities of the Series will be determined, if such amounts may be
determined by reference to an index based on a currency or currencies or by reference to a
commodity, commodity index, stock exchange index or financial index;
-8-
(17) the provisions, if any, relating to any collateral provided for the Securities of
the Series;
(18) any addition to or change in the covenants set forth in Articles 4 or 5 that
applies to Securities of the Series;
(19) any addition to or change in the Events of Default which applies to any Securities
of the Series, and any change in the right of the Trustee or the requisite Holders of such
Securities to declare the principal amount thereof due and payable pursuant to Section 6.2;
(20) the terms and conditions, if any, for conversion of the Securities into or
exchange of the Securities for shares of common stock or preferred stock of the Company that
apply to Securities of the Series;
(21) any depositories, interest rate calculation agents, exchange rate calculation
agents or other agents with respect to Securities of such Series if other than those
appointed herein;
(22) the terms and conditions, if any, upon which the Securities shall be subordinated
in right of payment to other Indebtedness of the Company;
(23) if applicable, that the Securities of the Series, in whole or any specified part,
shall be defeasible pursuant to Article 9; and
(24) any other terms of the Securities of the Series (which terms shall not be
inconsistent with the provisions of this Indenture, except as permitted by Section 8.1, but
which may modify or delete any provision of this Indenture insofar as it applies to such
Series).
All Securities of any one Series need not be issued at the same time, and may be issued from
time to time, consistent with the terms of this Indenture, if so provided by or pursuant to the
Board Resolution, supplemental indenture or Officers Certificate referred to above, however, the
authorized principal amount of any Series may not be increased to provide for issuances of
additional Securities of such Series, unless otherwise provided in such Board Resolution,
supplemental indenture or Officers Certificate.
2.3. EXECUTION AND AUTHENTICATION.
The Securities shall be executed on behalf of the Company by two Officers of the Company or an
Officer and an Assistant Secretary of the Company. Each such signature may be either manual or
facsimile. The Companys seal may be impressed, affixed, imprinted or reproduced on the Securities
and may be in facsimile form.
If an Officer whose signature is on a Security no longer holds that office at the time the
Security is authenticated, the Security shall nevertheless be valid.
-9-
A Security shall not be valid until authenticated by the manual signature of the Trustee or an
authenticating agent. The signature shall be conclusive evidence that the Security has been
authenticated under this Indenture. The Trustee shall at any time, and from time to time,
authenticate Securities for original issue in the principal amount provided in the Board
Resolution, supplemental indenture hereto or Officers Certificate, upon receipt by the Trustee of
a Company Order. Such Company Order may authorize authentication and delivery pursuant to oral or
electronic instructions from the Company or its duly authorized agent or agents, which oral
instructions shall be promptly confirmed in writing. Each Security shall be dated the date of its
authentication.
The aggregate principal amount of Securities of any Series outstanding at any time may not
exceed any limit upon the maximum principal amount for such Series set forth in the Board
Resolution, supplemental indenture hereto or Officers Certificate delivered pursuant to Section
2.2, except as provided in Section 2.8.
Prior to the issuance of Securities of any Series, the Trustee shall have received and
(subject to Section 7.1) shall be fully protected in relying on: (a) the Board Resolution,
supplemental indenture hereto or Officers Certificate establishing the form of the Securities of
that Series or of Securities within that Series and the terms of the Securities of that Series or
of Securities within that Series, (b) an Officers Certificate complying with Section 10.4, and (c)
an Opinion of Counsel complying with Section 10.4.
The Trustee shall have the right to decline to authenticate and deliver any Securities of any
Series: (a) if the Trustee, being advised in writing by outside counsel, determines that such
action may not lawfully be taken; or (b) if the Trustee in good faith by its board of directors or
trustees, executive committee or a trust committee of directors and/or vice-presidents shall
reasonably determine that such action would expose the Trustee to personal liability, or cause it
to have a conflict of interest with respect to Holders of any then outstanding Series of
Securities.
The Trustee may appoint an authenticating agent acceptable to the Company to authenticate
Securities. An authenticating agent may authenticate Securities whenever the Trustee may do so. Any
appointment shall be evidenced by an instrument signed by an authorized officer of the Trustee, a
copy of which shall be furnished to the Company. Each reference in this Indenture to authentication
by the Trustee includes authentication by such agent. An authenticating agent has the same rights
as an Agent to deal with the Company or an Affiliate of the Company.
2.4. REGISTRAR AND PAYING AGENT.
The Company shall maintain in each Place of Payment for any Series of Securities (i) an office
or agency where such Securities may be presented for registration of transfer or for exchange
(Registrar), (ii) an office or agency where such Securities may be presented for payment (Paying
Agent) (PROVIDED that the Company shall at all times maintain a Paying Agent in the Borough of
Manhattan, City of New York, State of New York (the New York Paying Agent), and PROVIDED,
FURTHER, that at the option of the Company payment of interest may be made by check mailed to the
address of the Person entitled thereto as such address shall appear in the register for the
Securities maintained by the Registrar), and (iii) an
-10-
office or agency where notices and demands to or upon the Company in respect of the Securities
and this Indenture may be served (Service Agent). The Registrar shall keep a register of the
Securities and of their transfer and exchange. The Company may have one or more co-registrars and
one or more additional paying agents. The Company shall give prompt written notice to the Trustee
of the location, and any change in the location, of such office or agency. If at any time the
Company shall fail to maintain any such required office, or to furnish the Trustee with the address
thereof, such presentations, surrenders, notices and demands may be made or served at the address
of the Trustee as set forth in Section 10.2. If the Company acts as Paying Agent, it shall
segregate the money held by it for the payment of principal of, and interest and premium, if any,
on, the Securities and hold it as a separate trust fund. The Company may change any Paying Agent,
Registrar, co-registrar or any other Agent without notice to any Securityholder.
The Company may also from time to time designate one or more other offices or agencies where
the Securities may be presented or surrendered for any or all such purposes, and may from time to
time rescind such designations; PROVIDED, HOWEVER, that no such designation or rescission shall in
any manner relieve the Company of its obligation to maintain an office or agency in each Place of
Payment for Securities of any Series for such purposes. The Company hereby initially designates the
Corporate Trust Office of the Trustee as such office of the Company. The Company shall give prompt
written notice to the Trustee of such designation or rescission, and of any change in the location
of any such other office or agency.
The Company shall enter into an appropriate agency agreement with any Registrar or Paying
Agent not a party to this Indenture. The agreement shall implement the provisions of this Indenture
that relate to such Agent. The Company shall notify the Trustee of the name and address of any such
Agent. If the Company fails to maintain a Registrar or Paying Agent, or agent for service of
notices and demands, or fails to give the foregoing notice, the Trustee shall act as such. The
Company hereby appoints the Trustee as the initial Registrar, Paying Agent and Service Agent for
each Series unless another Registrar, Paying Agent or Service Agent, as the case may be, is
appointed prior to the time Securities of that Series are first issued. The Company designates
, as the New York Paying Agent, with offices at
.
2.5. PAYING AGENT TO HOLD ASSETS IN TRUST.
The Trustee as Paying Agent shall, and the Company shall require each Paying Agent other than
the Trustee to agree in writing that each Paying Agent shall, hold in trust for the benefit of the
Holders of any Series of Securities or the Trustee all assets held by the Paying Agent for the
payment of principal of, or interest or premium, if any, on, such Series of Securities (whether
such assets have been distributed to it by the Company or any other obligor on such Series of
Securities), and the Company and the Paying Agent shall notify the Trustee in writing of any
Default by the Company (or any other obligor on such Series of Securities) in making any such
payment. The Company at any time may require a Paying Agent to distribute all assets held by it to
the Trustee and account for any assets disbursed, and the Trustee may, at any time during the
continuance of any payment default with respect to any Series of Securities, upon written request
to a Paying Agent, require such Paying Agent to distribute all assets held by it to the Trustee and
to account for any assets distributed. Upon distribution to the Trustee of all
-11-
assets that shall have been delivered by the Company to the Paying Agent, the Paying Agent
shall have no further liability for such assets.
2.6. SECURITYHOLDER LISTS.
The Trustee shall preserve in as current a form as is reasonably practicable the most recent
list available to it of the names and addresses of Securityholders of each Series of Securities. If
the Trustee is not the Registrar, the Company shall furnish to the Trustee as of each regular
record date for the payment of interest on the Securities of a Series and before each related
Interest Payment Date, and at such other times as the Trustee may request in writing, a list in
such form and as of such date as the Trustee may reasonably require of the names and addresses of
Securityholders of each Series of Securities.
2.7. TRANSFER AND EXCHANGE.
When Securities of a Series are presented to the Registrar with a request to register the
transfer thereof, the Registrar shall register the transfer as requested if the requirements of
applicable law are met, and when such Securities of a Series are presented to the Registrar with a
request to exchange them for an equal principal amount of other authorized denominations of
Securities of the same Series, the Registrar shall make the exchange as requested. To permit
transfers and exchanges, upon surrender of any Security for registration of transfer at the office
or agency maintained pursuant to Section 2.4, the Company shall execute and the Trustee shall
authenticate Securities at the Registrars request.
If Securities are issued as Global Securities, the provisions of Section 2.15 shall apply.
All Securities issued upon any registration of transfer or exchange of Securities shall be the
valid obligations of the Company, evidencing the same debt, and entitled to the same benefits under
this Indenture, as the Securities surrendered upon such registration of transfer or exchange.
Every Security presented or surrendered for registration of transfer or for exchange shall (if
so required by the Company or the Registrar or a co-registrar) be duly endorsed, or be accompanied
by a written instrument of transfer in form satisfactory to the Company and the Registrar or a
co-registrar, duly executed by the Holder thereof or his attorney duly authorized in writing.
Any exchange or transfer shall be without charge, except that the Company may require payment
by the Holder of a sum sufficient to cover any tax or other governmental charge that may be imposed
in relation to a transfer or exchange, but this provision shall not apply to any exchange pursuant
to Section 2.11, 3.6 or 8.5. The Trustee shall not be required to register transfers of Securities
of any Series, or to exchange Securities of any Series, for a period of 15 days before the record
date for selection for redemption of such Securities. The Trustee shall not be required to exchange
or register transfers of Securities of any Series called or being called for redemption in whole or
in part, except the unredeemed portion of such Security being redeemed in part.
-12-
2.8. REPLACEMENT SECURITIES.
If a mutilated Security is surrendered to the Trustee, or if the Holder of a Security presents
evidence to the satisfaction of the Company and the Trustee that the Security has been lost,
destroyed or wrongfully taken, the Company shall issue and the Trustee shall authenticate a
replacement Security of the same Series and of like tenor and principal amount and bearing a number
not contemporaneously outstanding. An indemnity bond may be required by the Company or the Trustee
that is sufficient in the reasonable judgment of the Company or the Trustee, as the case may be, to
protect the Company, the Trustee or any Agent from any loss which any of them may suffer if a
Security is replaced. The Company may charge such Holder for the Companys out-of-pocket expenses
in replacing a Security, including the fees and expenses of the Trustee. Every replacement Security
shall constitute an original additional obligation of the Company, whether or not the destroyed,
lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all
the benefits of this Indenture equally and proportionately with any and all other Securities of
that Series duly issued hereunder.
2.9. OUTSTANDING SECURITIES.
Securities outstanding at any time are all Securities authenticated by the Trustee, except for
those canceled by it, those delivered to it for cancellation and those described in this Section
2.9 as not outstanding.
If a Security is replaced pursuant to Section 2.8 (other than a mutilated Security surrendered
for replacement), it ceases to be outstanding until the Company and the Trustee receive proof
satisfactory to each of them that the replaced Security is held by a bona fide purchaser. A
mutilated Security ceases to be outstanding upon surrender of such Security and replacement thereof
pursuant to Section 2.8.
If a Paying Agent holds on a Redemption Date or the Stated Maturity money sufficient to pay
the principal of, premium, if any, and accrued interest on, Securities payable on that date, and is
not prohibited from paying such money to the Holders thereof pursuant to the terms of this
Indenture (PROVIDED, that if such Securities are to be redeemed, notice of such redemption has been
duly given pursuant to this Indenture or provision therefor satisfactory to the Trustee has been
made), then on and after that date such Securities cease to be outstanding and interest on them
ceases to accrue.
A Security does not cease to be outstanding solely because the Company or an Affiliate holds
the Security.
2.10. WHEN TREASURY SECURITIES DISREGARDED; DETERMINATION OF HOLDERS ACTION.
In determining whether the Holders of the required aggregate principal amount of the
Securities of any Series have concurred in any direction, waiver or consent, the Securities of any
Series owned by the Company or any other obligor on such Securities, or by any Affiliate of any of
them, shall be disregarded, except that for the purposes of determining whether the Trustee shall
be protected in relying on any such direction, waiver or consent, only Securities of such Series
which the Trustee actually knows are so owned shall be so disregarded. Securities of such
-13-
Series so owned which have been pledged in good faith shall not be disregarded if the pledgee
establishes to the satisfaction of the Trustee the pledgees right so to act with respect to the
Securities of such Series and that the pledgee is not the Company or any other obligor on the
Securities of such Series, or an Affiliate of any of them.
2.11. TEMPORARY SECURITIES.
Until definitive Securities are ready for delivery, the Company may prepare and execute, and
the Trustee shall authenticate, temporary Securities. Temporary Securities shall be substantially
in the form, and shall carry all rights, of definitive Securities, but may have variations that the
Company considers appropriate for temporary Securities. Without unreasonable delay, the Company
shall prepare and execute, and the Trustee shall authenticate, definitive Securities in exchange
for temporary Securities without charge to the Holder.
2.12. CANCELLATION.
All Securities surrendered for payment, redemption or registration of transfer or exchange, or
for credit against any sinking fund payment, shall, if surrendered to any Person other than the
Trustee, be delivered to the Trustee for cancellation. The Company may at any time deliver to the
Trustee for cancellation any Securities previously authenticated and delivered hereunder which the
Company may have acquired in any manner whatsoever, and may deliver to the Trustee (or to any other
Person for delivery to the Trustee) for cancellation any Securities previously authenticated
hereunder which the Company has not issued and sold. The Registrar and the Paying Agent shall
forward to the Trustee any Securities surrendered to them for transfer, exchange or payment. The
Trustee or, at the direction of the Trustee, the Registrar or the Paying Agent, and no one else,
shall cancel, and at the written request of the Company shall dispose of, all Securities
surrendered for transfer, exchange, payment or cancellation. If the Company shall acquire any of
the Securities, such acquisition shall not operate as a redemption or satisfaction of the
Indebtedness represented by such Securities unless and until the same are surrendered to the
Trustee for cancellation pursuant to this Section 2.12. No Securities shall be authenticated in
lieu of or in exchange for any Securities cancelled as provided in this Section 2.12, except as
expressly permitted by this Indenture.
2.13. PAYMENT OF INTEREST; DEFAULTED INTEREST; COMPUTATION OF INTEREST.
Except as otherwise provided as contemplated by Section 2.2 with respect to any Series of
Securities, interest on any Security which is payable, and is punctually paid or duly provided for,
on any Interest Payment Date shall be paid to the Person in whose name that Security is registered
at the close of business on the regular record date for such interest, as provided in the Board
Resolution, supplemental indenture hereto or Officers Certificate establishing the terms of such
Series.
If the Company defaults in a payment of interest on the Securities, it shall pay the defaulted
amounts, plus any interest payable on defaulted amounts pursuant to Section 4.1, to the Persons who
are Securityholders on a subsequent special record date, which date shall be the 15th day next
preceding the date fixed by the Company for the payment of defaulted interest, or
-14-
the next succeeding Business Day if such date is not a Business Day. At least 15 days before
the special record date, the Company shall mail or cause to be mailed to each Securityholder, with
a copy to the Trustee, a notice that states the special record date, the payment date and the
amount of defaulted interest, and interest payable on such defaulted interest, if any, to be paid.
Except as otherwise specified as contemplated by Section 2.2 for Securities of any Series,
interest on the Securities of each Series shall be computed on the basis of a 360-day year of
twelve 30-day months.
2.14. CUSIP NUMBER.
The Company in issuing the Securities may use one or more CUSIP numbers, and, if the Company
does so, the Trustee shall use the CUSIP number(s) in notices of redemption or exchange as a
convenience to Holders, PROVIDED, that any such notice may state that no representation is made as
to the correctness or accuracy of the CUSIP number(s) printed in the notice or on the Securities,
and that reliance may be placed only on the other identification numbers printed on the Securities,
and that any such redemption or exchange shall not be affected by any defect in or omission of any
such numbers.
2.15. PROVISIONS FOR GLOBAL SECURITIES.
(a) A Board Resolution, a supplemental indenture hereto or an Officers Certificate shall
establish whether the Securities of a Series shall be issued in whole or in part in the form of one
or more Global Securities, and the Depository for such Global Securities or Securities.
(b) Notwithstanding any provisions to the contrary contained in Section 2.7 and in addition
thereto, if, and only if the Depository (i) at any time is unwilling or unable to continue as
Depository for such Global Security or ceases to be a clearing agency registered under the Exchange
Act and (ii) a successor Depository is not appointed by the Company within 90 days after the date
the Company is so informed in writing or becomes aware of the same, the Company promptly will
execute and deliver to the Trustee definitive Securities, and the Trustee, upon receipt of a
Company Request for the authentication and delivery of such definitive Securities (which the
Company will promptly execute and deliver to the Trustee) and an Officers Certificate to the
effect that such Global Security shall be so exchangeable, will authenticate and deliver definitive
Securities, without charge, registered in such names and in such authorized denominations as the
Depository shall direct in writing (pursuant to instructions from its direct and indirect
participants or otherwise) in an aggregate principal amount equal to the principal amount of the
Global Security with like tenor and terms. Upon the exchange of a Global Security for definitive
Securities, such Global Security shall be canceled by the Trustee. Unless and until it is exchanged
in whole or in part for definitive Securities, as provided in this Section 2.15(b), a Global
Security may not be transferred except as a whole by the Depository with respect to such Global
Security to a nominee of such Depository, by a nominee of such Depository to such Depository or
another nominee of such Depository or by the Depository or any such nominee to a successor
Depository or a nominee of such a successor Depository.
-15-
(c) Any Global Security issued hereunder shall bear a legend in substantially the following
form:
This Security is a Global Security within the meaning of the Indenture hereinafter
referred to, and is registered in the name of the Depository or a nominee of the Depository.
This Security is exchangeable for Securities registered in the name of a Person other than
the Depository or its nominee only in the limited circumstances described in the Indenture,
and may not be transferred except as a whole by the Depository to a nominee of the
Depository, by a nominee of the Depository to the Depository or another nominee of the
Depository or by the Depository or any such nominee to a successor Depository or a nominee
of such a successor Depository.
(d) The Depository, as a Holder, may appoint agents and otherwise authorize participants to
give or take any request, demand, authorization, direction, notice, consent, waiver or other action
which a Holder is entitled to give or take under the Indenture.
(e) Notwithstanding the other provisions of this Indenture, unless otherwise specified as
contemplated by Section 2.2, payment of the principal of, and interest and premium, if any, on, any
Global Security shall be made to the Depository or its nominee in its capacity as the Holder
thereof.
(f) Except as provided in Section 2.15(e) above, the Company, the Trustee and any Agent shall
treat a Person as the Holder of such principal amount of outstanding Securities of any Series
represented by a Global Security as shall be specified in a written statement of the Depository
(which may be in the form of a participants list for such Series) with respect to such Global
Security, for purposes of obtaining any consents, declarations, waivers or directions required to
be given by the Holders pursuant to this Indenture, PROVIDED, that until the Trustee is so provided
with a written statement, it may treat the Depository or any other Person in whose name a Global
Security is registered as the owner of such Global Security for the purpose of receiving payment of
the principal of, and any premium and (subject to Section 2.13) any interest on, such Global
Security and for all other purposes whatsoever, and none of the Company, the Trustee or any agent
of the Company or the Trustee shall be affected by notice to the contrary.
2.16. PERSONS DEEMED OWNERS.
Prior to due presentment of a Security for registration of transfer, the Company, the Trustee,
the Registrar and any agent of the Company, the Registrar or the Trustee may treat the Person in
whose name such Security is registered as the owner of such Security for the purpose of receiving
payment of the principal of, and any premium and (subject to Section 2.13) any interest on, such
Security and for all other purposes whatsoever, and none of the Company, the Trustee, the Registrar
or any agent of the Company, the Trustee or the Registrar shall be affected by notice to the
contrary.
-16-
ARTICLE 3
REDEMPTION
3.1. NOTICES TO TRUSTEE.
The Company may, with respect to any Series of Securities, reserve the right to redeem and pay
the Series of Securities, or may covenant to redeem and pay the Series of Securities or any part
thereof, prior to the Stated Maturity thereof at such time and on such terms as provided for in
such Securities or the related Board Resolution, supplemental indenture or Officers Certificate.
If a Series of Securities is redeemable and the Company elects to redeem all or part of such Series
of Securities, it shall notify the Trustee of the Redemption Date and the principal amount of
Securities to be redeemed at least 45 days (unless a shorter notice shall be satisfactory to the
Trustee) before the Redemption Date. Any such notice may be canceled at any time prior to notice of
such redemption being mailed to any Holder, and shall thereby be void and of no effect.
3.2. SELECTION BY TRUSTEE OF SECURITIES TO BE REDEEMED.
Unless otherwise indicated for a particular Series of Securities by a Board Resolution, a
supplemental indenture or an Officers Certificate, if fewer than all of the Securities of a Series
are to be redeemed, the Trustee shall select the Securities of a Series to be redeemed pro rata, by
lot or by any other method that the Trustee considers fair and appropriate (unless the Company
specifically directs the Trustee otherwise) and, if such Securities are listed on any securities
exchange, by a method that complies with the requirements of such exchange.
The Trustee shall make the selection from Securities of a Series outstanding and not
previously called for redemption, and shall promptly notify the Company in writing of the
Securities selected for redemption and, in the case of any Security selected for partial
redemption, the principal amount thereof to be redeemed at least 35 but not more than 60 days
before the Redemption Date. Securities of a Series in denominations of $1,000 may be redeemed only
in whole. The Trustee may select for redemption portions of the principal of Securities of a Series
that have denominations larger than $1,000. Securities of a Series and portions of them it selects
shall be in amounts of $1,000 or, with respect to Securities of any Series issuable in other
denominations pursuant to Section 2.2(10), the minimum principal denomination for each Series and
integral multiples thereof. Provisions of this Indenture that apply to Securities called for
redemption also apply to portions of Securities called for redemption.
3.3. NOTICE OF REDEMPTION.
Unless otherwise indicated for a particular Series by Board Resolution, a supplemental
indenture hereto or an Officers Certificate, at least 30 days, and no more than 60 days, before a
Redemption Date, the Company shall mail, or cause to be mailed, a notice of redemption by
first-class mail to each Holder of Securities to be redeemed at his or her last address as the same
appears on the registry books maintained by the Registrar. The notice shall identify the Securities
to be redeemed and shall state:
(1) the Redemption Date;
-17-
(2) the redemption price, and that such redemption price shall become due and payable
on the Redemption Date;
(3) if any Security of a Series is being redeemed in part, the portion of the principal
amount of such Security of a Series to be redeemed and that, after the Redemption Date and
upon surrender of such Security of a Series, a new Security or Securities in principal
amount equal to the unredeemed portion will be issued;
(4) the name and address of the Paying Agent;
(5) that Securities of a Series called for redemption must be surrendered to the Paying
Agent to collect the redemption price, and the place or places where each such Security is
to be surrendered for such payment;
(6) that, unless the Company defaults in making the redemption payment, interest on the
Securities of a Series called for redemption ceases to accrue on the Redemption Date, and
the only remaining right of the Holders of such Securities is to receive payment of the
redemption price upon surrender to the Paying Agent of the Securities redeemed;
(7) if fewer than all of the Securities of a Series are to be redeemed, the
identification of the particular Securities of a Series (or portion thereof) to be redeemed,
as well as the aggregate principal amount of Securities of a Series to be redeemed and the
aggregate principal amount of Securities of a Series to be outstanding after such partial
redemption.
(8) the CUSIP number, if any, printed on the Securities being redeemed; and
(9) that no representation is made as to the correctness or accuracy of the CUSIP
number, if any, listed in such notice or printed on the Securities.
At the Companys request, the Trustee shall give the notice of redemption in the Companys
name and at the Companys sole expense.
3.4. EFFECT OF NOTICE OF REDEMPTION.
Once the notice of redemption described in Section 3.3 is mailed, Securities of a Series
called for redemption become due and payable on the Redemption Date and at the redemption price,
plus interest, if any, accrued to the Redemption Date. Upon surrender to the Trustee or Paying
Agent, such Securities of a Series shall be paid at the redemption price, plus accrued interest, if
any, to the Redemption Date; PROVIDED, that if the Redemption Date is after a regular interest
payment record date and on or prior to the next Interest Payment Date, the accrued interest shall
be payable to the Holder of the redeemed Securities registered on the relevant record date, as
specified by the Company in the notice to the Trustee pursuant to Section 3.1.
-18-
3.5. DEPOSIT OF REDEMPTION PRICE.
On or prior to the Redemption Date (but no later than 11:00 A.M. Eastern Time on such date),
the Company shall deposit with the Paying Agent money sufficient to pay the redemption price of and
accrued interest, if any, on all Securities to be redeemed on that date other than Securities or
portions thereof called for redemption on that date which have been delivered by the Company to the
Trustee for cancellation.
On and after any Redemption Date, if money sufficient to pay the redemption price of, and
accrued interest on, Securities called for redemption shall have been made available in accordance
with the preceding paragraph and the Company and the Paying Agent are not prohibited from paying
such moneys to Holders, the Securities called for redemption will cease to accrue interest and the
only right of the Holders of such Securities will be to receive payment of the redemption price of
and, subject to the proviso in Section 3.4, accrued and unpaid interest on such Securities to the
Redemption Date. If any Security called for redemption shall not be so paid, interest will be paid,
from the Redemption Date until such redemption payment is made, on the unpaid principal of the
Security and any interest or premium, if any, not paid on such unpaid principal, in each case, at
the rate and in the manner provided in the Securities.
3.6. SECURITIES REDEEMED IN PART.
Upon surrender of a Security of a Series that is redeemed in part, the Company shall execute,
and the Trustee shall authenticate, for a Holder a new Security of the same Series equal in
principal amount to the unredeemed portion of the Security surrendered.
ARTICLE 4
COVENANTS
4.1. PAYMENT OF SECURITIES.
The Company shall pay the principal of, and interest and premium, if any, on, each Series of
Securities on the dates and in the manner provided in such Securities and this Indenture.
An installment of principal or interest shall be considered paid on the date it is due if the
Trustee or Paying Agent holds on that date money designated for and sufficient to pay such
installment and is not prohibited from paying such money to the Holders pursuant to the terms of
this Indenture or otherwise.
The Company shall pay interest on overdue principal, and overdue interest, to the extent
lawful, at the rate specified in the Series of Securities.
4.2. SEC REPORTS.
The Company will deliver to the Trustee within 15 days after the filing of the same with the
SEC, copies of the quarterly and annual reports and of the information, documents and other
reports, if any, which the Company is required to file with the SEC pursuant to Section 13 or 15(d)
of the Exchange Act; PROVIDED, HOWEVER, that each such report or document will be
-19-
deemed to be so delivered to the Trustee if the Company files such report or document with the
SEC through the SECs EDGAR database no later than the time such report or document is required to
be filed with the SEC pursuant to the Exchange Act. Notwithstanding that the Company may not be
subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, the Company will
file with the SEC, to the extent permitted, and provide the Trustee with, such quarterly and annual
reports and such information, documents and other reports specified in Sections 13 and 15(d) of the
Exchange Act. The Company will also comply with the other provisions of TIA Section 314(a).
4.3. WAIVER OF STAY, EXTENSION OR USURY LAWS.
The Company covenants (to the extent that it may lawfully do so) that it will not at any time
insist upon, or plead (as a defense or otherwise) or in any manner whatsoever claim or take the
benefit or advantage of, any stay, extension, usury or other law which would prohibit or forgive
the Company from paying all or any portion of the principal of, and/or interest and premium, if
any, on, the Securities as contemplated herein, wherever enacted, now or at any time hereafter in
force, or which may affect the covenants or the performance of this Indenture; and the Company
hereby expressly waives (to the extent that they may lawfully do so) all benefit or advantage of
any such law, and covenants that it will not hinder, delay or impede the execution of any power
herein granted to the Trustee, but will suffer and permit the execution of every such power as
though no such law had been enacted.
4.4. COMPLIANCE CERTIFICATE.
(a) The Company shall deliver to the Trustee, within 120 days after the end of each fiscal
year of the Company, an Officers Certificate which complies with TIA Section 314(a)(4) stating
that a review of the activities of the Company and its Subsidiaries during such fiscal year has
been made under the supervision of the signing Officers with a view to determining whether the
Company has kept, observed, performed and fulfilled its obligations under this Indenture, and
further stating, as to each such Officer signing such certificate, that to the best of his or her
knowledge the Company has kept, observed, performed and fulfilled each and every covenant contained
in this Indenture and that there is no default in the performance or observance of any of the
terms, provisions and conditions hereof (or, if a Default or Event of Default shall have occurred,
describing all such Defaults or Events of Default of which he or she may have knowledge and what
action the Company is taking or proposes to take with respect thereto) and that to the best of his
or her knowledge no event has occurred and remains in existence by reason of which payments on
account of the principal of, or interest or premium, if any, on, the Securities is prohibited, or
if such event has occurred, a description of the event and what action the Company is taking or
proposes to take with respect thereto.
(b) (i) If any Default or Event of Default has occurred and is continuing or (ii) if any
Holder seeks to exercise any remedy hereunder with respect to a claimed Default under this
Indenture or the Securities, within five Business Days after the Company becoming aware of such
occurrence the Company shall deliver to the Trustee an Officers Certificate specifying such event,
notice or other action and what action the Company is taking or proposes to take with respect
thereto.
-20-
4.5. CORPORATE EXISTENCE.
Subject to Article 5, the Company shall do or cause to be done all things necessary to
preserve and keep in full force and effect its corporate existence, in accordance with the
organizational documents (as the same may be amended from time to time) of the Company and the
rights (charter and statutory), licenses and franchises of the Company; PROVIDED, HOWEVER, that the
Company shall not be required to preserve any such right, license or franchise, or its corporate
existence, if the Board of Directors shall determine that the preservation thereof is no longer
desirable in the conduct of the business of the Company and that the loss thereof is not adverse in
any material respect to the Holders.
ARTICLE 5
SUCCESSOR CORPORATION
5.1. LIMITATION ON CONSOLIDATION, MERGER AND SALE OF ASSETS.
(a) The Company will not, in any transaction or series of transactions, merge or consolidate
with or into, or sell, assign, convey, transfer, lease or otherwise dispose of all or substantially
all of its properties and assets (as an entirety or substantially as an entirety in one transaction
or a series of related transactions), to any Person or Persons, unless at the time of and after
giving effect thereto (i) either (A) if the transaction or series of transactions is a merger or
consolidation, the Company shall be the surviving Person of such merger or consolidation, or (B)
the Person formed by such consolidation or into which the Company is merged or to which the
properties and assets of the Company are transferred (any such surviving Person or transferee
Person being the Surviving Entity) shall be a corporation organized and existing under the laws
of the United States of America, any state thereof or the District of Columbia, or a corporation or
comparable legal entity organized under the laws of a foreign jurisdiction and shall expressly
assume by a supplemental indenture executed and delivered to the Trustee, in form reasonably
satisfactory to the Trustee, all of the obligations of the Company (including, without limitation,
the obligation to pay the principal of, and premium and interest, if any, on, the Securities and
the performance of the other covenants) under the Securities of each Series and this Indenture, and
in each case, this Indenture shall remain in full force and effect; and (ii) immediately before and
immediately after giving effect to such transaction or series of transactions on a pro forma basis
(including, without limitation, any Indebtedness incurred or anticipated to be incurred in
connection with or in respect of such transaction or series of transactions), no Default or Event
of Default shall have occurred and be continuing.
(b) In connection with any consolidation, merger or transfer of assets contemplated by this
Section 5.1, the Company shall deliver, or cause to be delivered, to the Trustee, in form and
substance reasonably satisfactory to the Trustee, an Officers Certificate and an Opinion of
Counsel, each stating that such consolidation, merger or transfer, and the supplemental indenture
in respect thereto, comply with this Section 5.1, and that all conditions precedent herein provided
for relating to such transaction or transactions have been complied with.
-21-
5.2. SUCCESSOR PERSON SUBSTITUTED.
Upon any consolidation, merger or transfer of all or substantially all of the assets of the
Company in accordance with Section 5.1 above, the successor corporation formed by such
consolidation, or into which the Company is merged or to which such transfer is made, shall succeed
to, and be substituted for, and may exercise every right and power of, the Company under this
Indenture with the same effect as if such successor corporation had been named as the Company
herein, and thereafter (except with respect to any such transfer which is a lease) the predecessor
corporation shall be relieved of all obligations and covenants under this Indenture and the
Securities.
ARTICLE 6
DEFAULTS AND REMEDIES
6.1. EVENTS OF DEFAULT.
Events of Default, wherever used herein with respect to Securities of any Series, means any
one of the following events, unless in the establishing Board Resolution, supplemental indenture or
Officers Certificate, it is provided that such Series shall not have the benefit of said Event of
Default:
(1) there is a default in the payment of any principal of, or premium, if any, on, the
Securities when the same becomes due and payable at Maturity, upon acceleration, redemption
or otherwise;
(2) there is a default in the payment of any interest on any Security of a Series when
the same becomes due and payable, and the Default continues for a period of 30 days;
(3) the Company defaults in the observance or performance of any other covenant in the
Securities of a Series or in this Indenture for 60 days after written notice from the
Trustee or the Holders of not less than 25% in the aggregate principal amount of the
Securities of such Series then outstanding, which notice must specify the Default, demand
that it be remedied and state that the notice is a Notice of Default;
(4) the Company or any Significant Subsidiary pursuant to or within the meaning of any
Bankruptcy Law:
(A) commences a voluntary case,
(B) consents to the entry of an order for relief against it in an involuntary
case,
(C) consents to the appointment of a Custodian of it or for all or
substantially all of its property,
(D) makes a general assignment for the benefit of its creditors, or
-22-
(E) generally is not paying its debts as they become due;
(5) a court of competent jurisdiction enters an order or decree under any Bankruptcy
Law that:
(A) is for relief against the Company or any Significant Subsidiary in an
involuntary case;
(B) appoints a Custodian of the Company or any Significant Subsidiary, or for
all or substantially all of the property of the Company or any Significant
Subsidiary; or
(C) orders the liquidation of the Company or any Significant Subsidiary, and
the order or decree remains unstayed and in effect for 90 consecutive days; or
(6) any other Event of Default provided with respect to Securities of that Series,
which is specified in a Board Resolution, a supplemental indenture hereto or an Officers
Certificate, in accordance with Section 2.2(19).
The term Bankruptcy Law means Title 11, U.S. Code, or any similar federal or state law for
the relief of debtors. The term Custodian means any receiver, trustee, assignee, liquidator or
similar official under any Bankruptcy Law.
The Trustee may withhold notice of any Default (except in the payment of the principal of, or
interest or premium, if any, on, the Securities) to the Holders of the Securities of any Series in
accordance with Section 7.5. When a Default is cured, it ceases to exist.
6.2. ACCELERATION.
If an Event of Default with respect to Securities of any Series at the time outstanding (other
than an Event of Default arising under Section 6.1(4) or (5)) occurs and is continuing, the Trustee
by written notice to the Company, or the Holders of not less than 25% in aggregate principal amount
of the Securities of that Series then outstanding by written notice to the Company and the Trustee,
may declare that the entire principal amount of all the Securities of that Series then outstanding
plus accrued and unpaid interest to the date of acceleration are immediately due and payable, in
which case such amounts shall become immediately due and payable; PROVIDED, HOWEVER, that after
such acceleration but before a judgment or decree based on such acceleration is obtained by the
Trustee, the Holders of a majority in aggregate principal amount of the outstanding Securities of
that Series may rescind and annul such acceleration and its consequences if (i) all existing Events
of Default, other than the nonpayment of accelerated principal, interest or premium, if any, that
has become due solely because of the acceleration, have been cured or waived, (ii) to the extent
the payment of such interest is lawful, interest on overdue installments of interest and overdue
principal, which has become due otherwise than by such declaration of acceleration, has been paid
and (iii) the rescission would not conflict with any judgment or decree. No such rescission shall
affect any subsequent Default or impair any right consequent thereto. In case an Event of Default
specified in Section 6.1(4) or (5) with respect to the Company occurs, such principal, premium, if
any, and interest amount
-23-
with respect to all of the Securities of that Series shall be due and payable immediately
without any declaration or other act on the part of the Trustee or the Holders of the Securities of
that Series.
6.3. REMEDIES.
If an Event of Default with respect to Securities of any Series at the time outstanding occurs
and is continuing, the Trustee may pursue any available remedy by proceeding at law or in equity to
collect the payment of the principal of, or interest and premium, if any, on, the Securities of
that Series, or to enforce the performance of any provision of the Securities of that Series or
this Indenture.
The Trustee may maintain a proceeding even if it does not possess any of the Securities of
that Series or does not produce any of them in the proceeding. A delay or omission by the Trustee
or any Securityholder in exercising any right or remedy accruing upon an Event of Default shall not
impair the right or remedy or constitute a waiver of or acquiescence in the Event of Default. No
remedy is exclusive of any other remedy. All available remedies are cumulative to the extent
permitted by law.
6.4. WAIVER OF PAST DEFAULTS AND EVENTS OF DEFAULT.
Subject to Sections 6.2, 6.7 and 8.2, the Holders of a majority in principal amount of the
Securities of any Series then outstanding have the right to waive any existing Default or Event of
Default with respect to such Series or compliance with any provision of this Indenture (with
respect to such Series) or the Securities of such Series. Upon any such waiver, such Default with
respect to such Series shall cease to exist, and any Event of Default with respect to such Series
arising therefrom shall be deemed to have been cured for every purpose of this Indenture; but no
such waiver shall extend to any subsequent or other Default or Event of Default or impair any right
consequent thereto. This Section 6.4 shall be in lieu of TIA Section 316(a)(1)(B), and TIA Section
316(a)(1)(B) is hereby expressly excluded from this Indenture and Section as permitted by the TIA.
6.5. CONTROL BY MAJORITY.
Subject to Sections 6.2, 6.7 and 8.2, the Holders of a majority in principal amount of the
Securities of any Series then outstanding may direct the time, method and place of conducting any
proceeding for any remedy available to the Trustee or exercising any trust or power conferred on
the Trustee by this Indenture with respect to such Series. The Trustee, however, may refuse to
follow any direction that conflicts with law or this Indenture, or that the Trustee determines may
be unduly prejudicial to the rights of another Securityholder, or that may involve the Trustee in
personal liability; PROVIDED, that the Trustee may take any other action deemed proper by the
Trustee which is not inconsistent with such direction. This Section 6.5 shall be in lieu of TIA
Section 316(a)(1)(A), and TIA Section 316(a)(1)(A) is hereby expressly excluded from this Indenture
and Section as permitted by the TIA.
-24-
6.6. LIMITATION ON SUITS.
Subject to Section 6.7, a Securityholder may not institute any proceeding or pursue any remedy
with respect to this Indenture or the Securities of a Series unless:
(1) the Holder gives to the Trustee written notice of a continuing Event of Default
with respect to the Securities of that Series;
(2) the Holders of at least 25% in aggregate principal amount of the Securities of such
Series then outstanding make a written request to the Trustee to pursue the remedy;
(3) such Holder or Holders offer to the Trustee indemnity reasonably satisfactory to
the Trustee against any loss, liability or expense to be incurred in compliance with such
request;
(4) the Trustee does not comply with the request within 60 days after receipt of the
request and the offer of indemnity; and
(5) no direction inconsistent with such written request has been given to the Trustee
during such 60-day period by the Holders of a majority in aggregate principal amount of the
Securities of such Series then outstanding.
A Securityholder may not use this Indenture to prejudice the rights of another Securityholder,
or to obtain a preference or priority over another Securityholder.
6.7. RIGHTS OF HOLDERS TO RECEIVE PAYMENT.
Notwithstanding any other provision of this Indenture, the right of any Holder of a Security
of a Series to receive payment of the principal of, and interest and premium, if any, on, the
Security of such Series on or after the respective due dates expressed in the Security of such
Series, or to bring suit for the enforcement of any such payment on or after such respective dates,
is absolute and unconditional, and shall not be impaired or affected without the consent of the
Holder.
6.8. COLLECTION SUIT BY TRUSTEE.
If an Event of Default in payment of principal, interest or premium, if any, specified in
Section 6.1(1) or (2) with respect to Securities of any Series at the time outstanding occurs and
is continuing, the Trustee may recover judgment in its own name and as trustee of an express trust
against the Company (or any other obligor on the Securities of that Series) for the whole amount of
unpaid principal and premium, if any, and accrued interest remaining unpaid, together with interest
on overdue principal and premium, if any, and, to the extent that payment of such interest is
lawful, interest on overdue installments of interest, in each case at the rate then borne by the
Securities of that Series, and such further amounts as shall be sufficient to cover the costs and
expenses of collection, including the reasonable compensation, expenses, disbursements and advances
of the Trustee, its agents and counsel, as set forth in Section 7.7.
-25-
6.9. TRUSTEE MAY FILE PROOFS OF CLAIM.
The Trustee may file such proofs of claim and other papers or documents, and take other
actions (including sitting on a committee of creditors), as may be necessary or advisable in order
to have the claims of the Trustee (including any claim for the reasonable compensation, expenses,
disbursements and advances of the Trustee, its agents and counsel) and the Securityholders allowed
in any judicial proceedings relative to the Company (or any other obligor on the Securities), any
of their respective creditors or any of their respective property, and the Trustee shall be
entitled and empowered to collect and receive any monies or other property payable or deliverable
on any such claims, and to distribute the same after deduction of its charges and expenses to the
extent that any such charges and expenses are not paid out of the estate in any such proceedings,
and any custodian in any such judicial proceeding is hereby authorized by each Securityholder to
make such payments to the Trustee, and in the event that the Trustee shall consent to the making of
such payments directly to the Securityholders, to pay to the Trustee any amount due to it for the
reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and
counsel, and any other amounts due the Trustee under Section 7.7.
Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to,
or accept or adopt on behalf of any Securityholder, any plan of reorganization, arrangement,
adjustment or composition affecting the Securities of a Series or the rights of any Holder thereof,
or to authorize the Trustee to vote in respect of the claim of any Securityholder in any such
proceedings.
6.10. PRIORITIES.
If the Trustee collects any money pursuant to this Article 6, it shall pay out the money in
the following order:
FIRST: to the Trustee for amounts due under Section 7.7;
SECOND: to Securityholders for amounts then due and unpaid for the principal of, and
interest and premium, if any, on, the Securities in respect of which, or for the benefit of
which, such money has been collected, ratably, without preference or priority of any kind,
according to the amounts due and payable on such Securities; for principal and any premium
and interest, respectively; and
THIRD: to the Company.
The Trustee may fix a record date and payment date for any payment to Securityholders pursuant
to this Section 6.10. At least 15 days before such record date, the Trustee shall mail to each
Securityholder a notice that states the record date, the payment date and amount to be paid.
6.11. UNDERTAKING FOR COSTS.
In any suit for the enforcement of any right or remedy under this Indenture, or in any suit
against the Trustee for any action taken or omitted by it as Trustee, a court in its discretion may
require the filing by any party litigant in the suit of an undertaking to pay the costs of the
suit,
-26-
and the court in its discretion may assess reasonable costs, including reasonable attorneys
fees, against any party litigant in the suit, having due regard to the merits and good faith of the
claims or defenses made by the party litigant. This Section 6.11 does not apply to a suit by the
Trustee, a suit by a Holder pursuant to Section 6.7 or a suit by Holders of more than 10% in
principal amount of the Securities of a Series then outstanding.
ARTICLE 7
TRUSTEE
7.1. DUTIES OF TRUSTEE.
(a) If an Event of Default has occurred and is continuing, the Trustee shall exercise such of
the rights and powers vested in it by this Indenture and use the same degree of care and skill in
their exercise as a prudent Person would exercise or use under the same circumstances in the
conduct of his own affairs.
(b) Except during the continuance of an Event of Default:
(1) The Trustee need perform only those duties that are specifically set forth
in this Indenture, and no covenants or obligations shall be implied in this
Indenture against the Trustee.
(2) In the absence of bad faith on its part, the Trustee may conclusively rely,
as to the truth of the statements and the correctness of the opinions expressed
therein, upon certificates or opinions furnished to the Trustee and conforming to
the requirements of this Indenture, but, in the case of any such certificates or
opinions which by any provision hereof are specifically required to be furnished to
the Trustee, the Trustee shall be under a duty to examine the same to determine
whether or not they conform to the requirements of this Indenture.
(c) The Trustee may not be relieved from liability for its own negligent action, its own
negligent failure to act or its own willful misconduct, except that:
(1) This paragraph does not limit the effect of paragraph (b) of this Section
7.1.
(2) The Trustee shall not be liable for any error of judgment made in good
faith by a Responsible Officer, unless it is proved that the Trustee was negligent
in ascertaining the pertinent facts.
(3) The Trustee shall not be liable with respect to any action it takes or
omits to take in good faith in accordance with a direction received by it pursuant
to Sections 6.2 and 6.5.
(d) No provision of this Indenture shall require the Trustee to expend or risk its own funds,
or otherwise incur any financial liability, in the performance of any of its rights or
-27-
powers if it
shall have reasonable grounds for believing that repayment of such funds or adequate indemnity
satisfactory to it against such risk or liability is not reasonably assured to it.
(e) Whether or not therein expressly so provided, paragraphs (a), (b), (c) and (d) of this
Section 7.1 shall govern every provision of this Indenture that in any way relates to the Trustee.
(f) The Trustee and Paying Agent shall not be liable for interest on any money received by
either of them, except as the Trustee and Paying Agent may agree in writing with the Company. Money
held in trust by the Trustee need not be segregated from other funds except to the extent required
by the law.
(g) The Paying Agent, the Registrar and any authenticating agent shall be entitled to the
protections, immunities and standard of care set forth in paragraphs (a), (b), (c), (d) and (f) of
this Section 7.1 and in Section 7.2 with respect to the Trustee.
7.2. RIGHTS OF TRUSTEE.
(a) Subject to Section 7.1:
(1) The Trustee may rely on, and shall be protected in acting or refraining
from acting upon, any document reasonably believed by it to be genuine and to have
been signed or presented by the proper Person. The Trustee need not investigate any
fact or matter stated in the document.
(2) Before the Trustee acts or refrains from acting, it may require an
Officers Certificate or an Opinion of Counsel, or both, which shall conform to the
provisions of Section 10.5. The Trustee shall be protected and shall not be liable
for any action it takes or omits to take in good faith in reliance on such
certificate or opinion.
(3) The Trustee may act through agents and attorneys, and shall not be
responsible for the misconduct or negligence of any agent appointed by it with due
care.
(4) The Trustee shall not be liable for any action it takes or omits to take in
good faith which it reasonably believes to be authorized or within its rights or
powers.
(5) The Trustee may consult with counsel reasonably acceptable to the Trustee,
which may be counsel to the Company, and the advice or opinion of such counsel as to
matters of law shall be full and complete authorization and protection from
liability in respect of any action taken, omitted or suffered by it hereunder in
good faith and in accordance with the advice or opinion of such counsel.
(6) The Trustee shall be under no obligation to exercise any of the rights or
powers vested in it by this Indenture at the request, order or direction of
-28-
any of
the Holders pursuant to the provisions of this Indenture, unless such Holders shall
have offered to the Trustee reasonable security or indemnity against the costs,
expenses and liabilities which may be incurred therein or thereby.
(7) The Trustee shall not be deemed to have knowledge of any fact or matter
(including, without limitation, a Default or Event of Default) unless such fact or
matter is known to a Responsible Officer of the Trustee.
(8) Unless otherwise expressly provided herein or in the Securities of a Series
or the related Board Resolution, supplemental indenture or Officers Certificate,
the Trustee shall not have any responsibility with respect to reports, notices,
certificates or other documents filed with it hereunder, except to make them
available for inspection, at reasonable times, by Securityholders, it being
understood that delivery of such reports, information and documents to the Trustee
is for informational purposes only and the Trustees receipt of such shall not
constitute constructive notice of any information contained therein or determinable
from information contained therein, including the Companys compliance with any of
its covenants hereunder (except as set forth in Section 4.4).
7.3. INDIVIDUAL RIGHTS OF TRUSTEE.
The Trustee in its individual or any other capacity may become the owner or pledgee of
Securities, and may make loans to, accept deposits from, perform services for or otherwise deal
with the Company, or any Affiliate thereof, with the same rights it would have if it were not
Trustee. Any Agent may do the same with like rights. The Trustee, however, shall be subject to
Sections 7.10 and 7.11.
7.4. TRUSTEES DISCLAIMER.
The Trustee makes no representation as to the validity or adequacy of this Indenture or the
Securities (except that the Trustee represents that it is duly authorized to execute and deliver
this Indenture and authenticate the Securities and perform its obligations hereunder), and the
Trustee shall not be accountable for the Companys use of the proceeds from the sale of Securities
or any money paid to the Company pursuant to the terms of this Indenture, and the Trustee shall not
be responsible for any statement in the Securities other than its certificates of authentication.
7.5. NOTICE OF DEFAULT.
If a Default or an Event of Default occurs and is continuing with respect to the Securities of
any Series, and if it is known to the Trustee, the Trustee shall mail to each Securityholder of the
Securities of that Series notice of the Default or the Event of Default, as the case may be, within
90 days after it occurs or, if later, after a Responsible Officer of the Trustee has knowledge of
such Default or Event of Default (except if such Default or Event of Default has been validly cured
or waived before the giving of such notice). Except in the case of a Default or an Event of Default
in payment of the principal of, or interest or premium, if any, on, any Security of any Series, the
Trustee may withhold the notice if and so long as the Board of
-29-
Directors of the Trustee, the
executive committee or any trust committee of such board and/or its Responsible Officers in good
faith determine(s) that withholding the notice is in the interests of the Securityholders of that
Series.
7.6. REPORTS BY TRUSTEE TO HOLDERS.
If and to the extent required by the TIA, within 60 days after April 1 of each year,
commencing the April 1 following the date of this Indenture, the Trustee shall mail to each
Securityholder a brief report dated as of such April 1 that complies with TIA Section 313(a). The
Trustee also shall comply with TIA Sections 313(b) and 313(c).
A copy of each report at the time of its mailing to Securityholders shall be filed with the
SEC and any stock exchange on which the Securities of that Series are listed. The Company shall
promptly notify the Trustee when the Securities of any Series are listed on any stock exchange or
any delisting thereof, and the Trustee shall comply with TIA Section 313(d).
7.7. COMPENSATION AND INDEMNITY.
The Company shall pay to the Trustee from time to time reasonable compensation for its
services. The Trustees compensation shall not be limited by any provision of law on compensation
of a trustee of an express trust. The Company shall reimburse the Trustee within 45 days after
receipt of request for all reasonable out-of-pocket disbursements and expenses incurred or made by
it in connection with its duties under this Indenture, including the reasonable compensation,
disbursements and expenses of the Trustees agents and counsel.
The Company shall indemnify the Trustee for, and hold it harmless against, any and all loss or
liability incurred by it in connection with the acceptance or performance of its duties under this
Indenture including the reasonable costs and expenses of defending itself against any claim or
liability in connection with the exercise or performance of any of its powers or duties hereunder.
The Trustee shall notify the Company promptly of any claim asserted against the Trustee for which
it may seek indemnity.
The failure by the Trustee to so notify the Company shall not however relieve the Company of
its obligations. Notwithstanding the foregoing, the Company need not reimburse the Trustee for any
expense or indemnify it against any loss or liability incurred by the Trustee through its
negligence or bad faith. To secure the payment obligations of the Company in this Section 7.7, the
Trustee shall have a lien prior to the Securities of any Series on all money or property held or
collected by the Trustee except such money or property held in trust to pay the principal of,
interest and premium, if any, on particular Securities of that Series.
When the Trustee incurs expenses or renders services after an Event of Default specified in
Section 6.1(4) or (5) occurs, the expenses and the compensation for the services are intended to
constitute expenses of administration under any Bankruptcy Law.
For purposes of this Section 7.7, the term Trustee shall include any trustee appointed
pursuant to this Article 7.
-30-
7.8. REPLACEMENT OF TRUSTEE.
The Trustee may resign with respect to the Securities of one or more Series by so notifying
the Company in writing at least 90 days in advance of such resignation.
The Holders of a majority in principal amount of the outstanding Securities of any Series may
remove the Trustee with respect to that Series by notifying the removed Trustee in writing and may
appoint a successor Trustee with respect to that Series with the consent of the Company, which
consent shall not be unreasonably withheld. The Company may remove the Trustee with respect to that
Series at its election if:
(1) the Trustee fails to comply with, or ceases to be eligible under, Section 7.10;
(2) the Trustee is adjudged a bankrupt or an insolvent, or an order for relief is
entered with respect to the Trustee, under any Bankruptcy Law;
(3) a Custodian or other public officer takes charge of the Trustee or its property; or
(4) the Trustee otherwise becomes incapable of acting.
(5) If the Trustee resigns or is removed, or if a vacancy exists in the office of
Trustee, with respect to any Series of Securities for any reason, the Company shall promptly
appoint, by Board Resolution, a successor Trustee.
If a successor Trustee with respect to the Securities of one or more Series does not take
office within 60 days after the retiring Trustee resigns or is removed, the retiring Trustee, the
Company or the Holders of at least 10% in principal amount of the outstanding Securities of the
applicable Series may petition any court of competent jurisdiction for the appointment of a
successor Trustee.
If the Trustee with respect to the Securities of one or more Series fails to comply with
Section 7.10, any Securityholder of the applicable Series may petition any court of competent
jurisdiction for the removal of the Trustee and the appointment of a successor Trustee.
A successor Trustee shall deliver a written acceptance of its appointment to the retiring
Trustee and to the Company. Immediately following such delivery, (i) the retiring Trustee with
respect to one or more Series shall, subject to its rights under Section 7.7, transfer all property
held by it as Trustee with respect to such Series to the successor Trustee, (ii) the resignation or
removal of the retiring Trustee shall become effective and (iii) the successor Trustee with respect
to such Series shall have all the rights, powers and duties of the Trustee under this Indenture. A
successor Trustee with respect to the Securities of one or more Series shall mail notice of its
succession to each Securityholder of such Series.
-31-
7.9. SUCCESSOR TRUSTEE BY CONSOLIDATION, MERGER OR CONVERSION.
If the Trustee, or any Agent, consolidates with, merges or converts into, or transfers all or
substantially all of its corporate trust assets to, another corporation, subject to Section 7.10,
the successor corporation without any further act shall be the successor Trustee or Agent, as the
case may be.
7.10. ELIGIBILITY; DISQUALIFICATION.
This Indenture shall always have a Trustee who satisfies the requirements of TIA Sections
310(a)(1), (2) and (5) in every respect. The Trustee (or in the case of a Trustee that is a Person
included in a bank holding company system, the related bank holding company) shall have a combined
capital and surplus of at least $100,000,000 as set forth in its most recent published annual
report of condition. The Trustee shall comply with TIA Section 310(b), including the provision in
Section 310(b)(1). In addition, if the Trustee is a Person included in a bank holding company
system, the Trustee, independently of such bank holding company, shall meet the capital
requirements of TIA Section 310(a)(2). If at any time the Trustee shall cease to be eligible in
accordance with the provisions of this Section 7.10, it shall resign immediately in the manner and
with the effect specified in this Article 7.
7.11. PREFERENTIAL COLLECTION OF CLAIMS AGAINST COMPANY.
The Trustee shall comply with TIA Section 311(a), excluding any creditor relationship listed
in TIA Section 311(b). A Trustee who has resigned or been removed shall be subject to TIA Section
311(a) to the extent indicated therein.
7.12. PAYING AGENTS.
The Company shall cause each Paying Agent other than the Trustee to execute and deliver to it
and the Trustee an instrument in which such agent shall agree with the Trustee, subject to the
provisions of this Section 7.12:
(1) that it will hold all sums held by it as agent for the payment of the principal of,
or interest or premium, if any, on, the Securities (whether such sums have been paid to it
by the Company or by any obligor on the Securities) in trust for the benefit of Holders of
the Securities or the Trustee;
(2) that it will at any time during the continuance of any Event of Default, upon
written request from the Trustee, deliver to the Trustee all sums so held in trust by it
together with a full accounting thereof; and
(3) that it will give the Trustee written notice within three Business Days after any
failure of the Company (or by any obligor on the Securities) in the payment of any
installment of the principal of, or interest or premium, if any, on, the Securities when the
same shall be due and payable.
-32-
ARTICLE 8
AMENDMENTS, SUPPLEMENTS AND WAIVERS
8.1. WITHOUT CONSENT OF HOLDERS.
The Company, when authorized by a Board Resolution, and the Trustee may amend or supplement
this Indenture or the Securities of one or more Series without notice to or consent of any
Securityholder:
(1) to comply with Section 5.1;
(2) to provide for certificated Securities in addition to uncertificated Securities;
(3) to comply with any requirements of the SEC under the TIA;
(4) to cure any ambiguity, defect or inconsistency, or to make any other change herein
or in the Securities that does not materially and adversely affect the rights of any
Securityholder;
(5) to provide for the issuance of, and establish the form and terms and conditions of,
Securities of any Series as permitted by this Indenture; or
(6) to evidence and provide for the acceptance of appointment hereunder by a successor
Trustee with respect to the Securities of one or more Series, and to add to or change any of
the provisions of this Indenture as shall be necessary to provide for or facilitate the
administration of the trusts hereunder by more than one Trustee.
The Trustee is hereby authorized to join with the Company in the execution of any supplemental
indenture authorized or permitted by the terms of this Indenture, and to make any further
appropriate agreements and stipulations which may be therein contained, but the Trustee shall not
be obligated to enter into any such supplemental indenture which adversely affects its own rights,
duties or immunities under this Indenture.
8.2. WITH CONSENT OF HOLDERS.
(a) The Company, when authorized by a Board Resolution, and the Trustee may amend or
supplement this Indenture or the Securities of one or more Series with the written consent of the
Holders of not less than a majority in aggregate principal amount of the outstanding Securities of
such Series affected by such amendment or supplement without notice to any Securityholder. The
Holders of not less than a majority in aggregate principal amount of the outstanding Securities of
each such Series affected by such amendment or supplement may waive compliance by the Company in a
particular instance with any provision of this Indenture or the Securities of such Series without
notice to any Securityholder. Subject to Section 8.4, without the consent of each Securityholder
affected, however, an amendment, supplement or waiver may not:
-33-
(1) reduce the amount of Securities whose Holders must consent to an amendment,
supplement or waiver to this Indenture or the Securities;
(2) reduce the rate of, or change the time for payment of, interest on any
Security;
(3) reduce the principal, or change the Stated Maturity, of any Security, or
reduce the amount of, or postpone the date fixed for, the payment of any sinking
fund or analogous obligation;
(4) make any Security payable in money other than that stated in the Security;
(5) change the amount or time of any payment required by the Securities, or
reduce the premium payable upon any redemption of the Securities, or change the time
before which no such redemption may be made;
(6) waive a Default or Event of Default in the payment of the principal of, or
interest or premium, if any, on, any Security (except a rescission of acceleration
of the Securities of any Series by the Holders of at least a majority in principal
amount of the outstanding Securities of such Series and a waiver of the payment
default that resulted from such acceleration);
(7) waive a redemption payment with respect to any Security, or change any of
the provisions with respect to the redemption of any Securities;
(8) make any changes in Section 6.6 or this Section 8.2, except to increase any
percentage of Securities the Holders of which must consent to any matter; or
(9) take any other action otherwise prohibited by this Indenture to be taken
without the consent of each Holder affected thereby.
(b) Upon the request of the Company, accompanied by a Board Resolution authorizing the
execution of any such supplemental indenture, and upon the receipt by the Trustee of evidence
reasonably satisfactory to the Trustee of the consent of the Securityholders as aforesaid and of
the documents described in Section 8.6, the Trustee shall join with the Company in the execution of
such supplemental indenture, unless such supplemental indenture affects the Trustees own rights,
duties or immunities under this Indenture, in which case the Trustee may in its discretion, but
shall not be obligated to, enter into such supplemental indenture.
(c) It shall not be necessary for the consent of the Holders under this section to approve the
particular form of any proposed amendment, supplement or waiver, but it shall be sufficient if such
consent approves the substance thereof.
After an amendment or supplement under this Section becomes effective, the Company shall mail
to Securityholders a notice briefly describing the amendment or supplement. Any
-34-
failure of the Company to mail any such notice, or any defect therein, shall not, however, in any way impair or
affect the validity of any supplemental indenture.
8.3. COMPLIANCE WITH TRUST INDENTURE ACT.
Every amendment to, or supplement of, this Indenture or the Securities shall comply with the
TIA as then in effect.
8.4. REVOCATION AND EFFECT OF CONSENTS.
Until an amendment, supplement, waiver or other action becomes effective, a consent to it by a
Holder of a Security is a continuing consent conclusive and binding upon such Holder and every
subsequent Holder of the same Security or portion thereof, and of any Security issued upon the
transfer thereof or in exchange therefor or in place thereof, even if notation of the consent is
not made on any such Security. Any such Holder or subsequent Holder, however, may revoke the
consent as to his Security or portion of a Security, if the Trustee receives the notice of
revocation before the date the amendment, supplement, waiver or other action becomes effective.
The Company may, but shall not be obligated to, fix a record date for the purpose of
determining the Holders entitled to consent to any amendment, supplement or waiver, which record
date shall be at least 30 days prior to the first solicitation of such consent. If a record date is
fixed, then, notwithstanding the preceding paragraph, those Persons who were Holders at such record
date (or their duly designated proxies), and only such Persons, shall be entitled to consent to
such amendment, supplement or waiver, or to revoke any consent previously given, whether or not
such Persons continue to be Holders after such record date.
After an amendment, supplement, waiver or other action becomes effective, it shall bind every
Securityholder, unless it makes a change described in any of clauses (1) through (9) of Section
8.2. In that case, the amendment, supplement, waiver or other action shall bind each Holder of a
Security who has consented to it and every subsequent Holder of a Security or portion of a Security
that evidences the same debt as the consenting Holders Security; PROVIDED, that any such waiver
shall not impair or affect the right of any Holder to receive payment of the principal of, and
interest and premium, if any, on, a Security, on or after the respective due dates expressed in
such Security, or to bring suit for the enforcement of any such payment on or after such respective
dates without the consent of such Holder.
8.5. NOTATION ON OR EXCHANGE OF SECURITIES.
If an amendment, supplement or waiver changes the terms of a Security of any Series, the
Trustee may request the Holder of such Security to deliver it to the Trustee. In such case, the
Trustee shall place an appropriate notation on such Security about the changed terms and return it
to the Holder. Alternatively, the Company, in exchange for such Security, may issue, and the
Trustee shall authenticate, a new security that reflects the changed terms. Failure to make the
appropriate notation or issue a new Security shall not affect the validity and effect of such
amendment, supplement or waiver.
-35-
8.6. TRUSTEE TO SIGN AMENDMENTS, ETC.
The Trustee shall sign any amendment, supplement or waiver authorized pursuant to this Article
8 if the amendment, supplement or waiver does not adversely affect the rights, duties, liabilities
or immunities of the Trustee. If it does, the Trustee may, but need not, sign it. In signing or
refusing to sign such amendment, supplement or waiver the Trustee shall be entitled to receive and,
subject to Section 7.1, shall be fully protected in relying upon an Officers Certificate and an
Opinion of Counsel stating that such amendment, supplement or waiver is authorized or permitted by
this Indenture. The Company may not sign an amendment or supplement until the Board of Directors of
the Company approves it.
ARTICLE 9
DISCHARGE OF INDENTURE; DEFEASANCE
9.1. DISCHARGE OF INDENTURE.
The Company may terminate its obligations under the Securities of any Series and this
Indenture with respect to such Series, except the obligations referred to in the last paragraph of
this Section 9.1, if there shall have been canceled by the Trustee, or delivered to the Trustee for
cancellation, all Securities of such Series theretofore authenticated and delivered (other than
any Securities of such Series that are asserted to have been destroyed, lost or stolen and that
shall have been replaced as provided in Section 2.8) and the Company has paid all sums payable by
it hereunder or deposited all required sums with the Trustee.
After such delivery the Trustee upon request shall acknowledge in a writing prepared by or on
behalf of the Company the discharge of the Companys obligations under the Securities of such
Series and this Indenture, except for those surviving obligations specified below.
Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the
Company in Sections 7.7, 9.5 and 9.6 shall survive.
9.2. LEGAL DEFEASANCE.
The Company may at its option, by Board Resolution, be discharged from its obligations with
respect to the Securities of any Series on the date upon which the conditions set forth in Section
9.4 below are satisfied (hereinafter, Legal Defeasance). For this purpose, such Legal Defeasance
means that the Company shall be deemed to have paid and discharged the entire indebtedness
represented by the Securities of such Series and to have satisfied all its other obligations under
such Securities and this Indenture insofar as such Securities are concerned (and the Trustee, at
the expense of the Company, shall, subject to Section 9.6, execute proper instruments acknowledging
the same, as are delivered to it by the Company), except for the following, which shall survive
until otherwise terminated or discharged hereunder: (A) the rights of Holders of outstanding
Securities of such Series to receive solely from the trust funds described in Section 9.4 and as
more fully set forth in such section, payments in respect of the principal of, and interest and
premium, if any, on, the Securities of such Series when such payments are due, (B) the Companys
obligations with respect to the Securities of such Series under Sections 2.4, 2.5, 2.6, 2.7, 2.8
and 2.9, (C) the rights, powers, trusts, duties and immunities
-36-
of the Trustee hereunder (including claims of, or payments to, the Trustee under or pursuant to Section 7.7) and (D) this Article 9.
Subject to compliance with this Article 9, the Company may exercise its option under this Section
9.2 with respect to the Securities of any Series notwithstanding the prior exercise of its option
under Section 9.3 below with respect to the Securities of such Series.
9.3. COVENANT DEFEASANCE.
At the option of the Company, pursuant to a Board Resolution, the Company shall be released
from its obligations with respect to the outstanding Securities of any Series under Sections 4.2
through 4.5, inclusive, and Section 5.1, with respect to the outstanding Securities of such Series,
on and after the date the conditions set forth in Section 9.4 are satisfied (hereinafter, Covenant
Defeasance). For this purpose, such Covenant Defeasance means that the Company may omit to comply
with and shall have no liability in respect of any term, condition or limitation set forth in any
such specified section or portion thereof, whether directly or indirectly by reason of any
reference elsewhere herein to any such specified Section or portion thereof or by reason of any
reference in any such specified section or portion thereof to any other provision herein or in any
other document, but the remainder of this Indenture and the Securities of any Series shall be
unaffected thereby.
9.4. CONDITIONS TO LEGAL DEFEASANCE OR COVENANT DEFEASANCE.
The following shall be the conditions to application of Section 9.2 or Section 9.3 to the
outstanding Securities of a Series:
(1) the Company shall irrevocably have deposited or caused to be deposited with the
Trustee (or another trustee satisfying the requirements of Section 7.10 who shall agree to
comply with the provisions of this Article 9 applicable to it) as funds in trust for the
purpose of making the following payments, specifically pledged as security for, and
dedicated solely to, the benefit of the Holders of the Securities, (A) money in an amount,
or (B) U.S. Government Obligations or Foreign Government Obligations which through the
scheduled payment of principal and interest in respect thereof in accordance with their
terms will provide, not later than the due date of any payment, money in an amount, or (C) a
combination thereof, sufficient, in the opinion of a nationally recognized firm of
independent public accountants expressed in a written certification thereof delivered to the
Trustee, to pay and discharge, and which shall be applied by the Trustee (or other
qualifying trustee) to pay and discharge, the principal of, and accrued interest and
premium, if any, on, the outstanding Securities of such Series at the Stated Maturity of
such principal, interest or premium, if any, or on dates for payment and redemption of such
principal, interest and premium, if any, selected in accordance with the terms of this
Indenture and of the Securities of such Series;
(2) no Event of Default or Default with respect to the Securities of such Series shall
have occurred and be continuing on the date of such deposit, or shall have occurred and be
continuing at any time during the period ending on the 91st day after the date of such
deposit or, if longer, ending on the day following the expiration of the longest
-37-
preference period under any Bankruptcy Law applicable to the Company in respect of such deposit as
specified in the Opinion of Counsel identified in paragraph (8) below (it being understood
that this condition shall not be deemed satisfied until the expiration of such period);
(3) such Legal Defeasance or Covenant Defeasance shall not cause the Trustee to have a
conflicting interest for purposes of the TIA with respect to any securities of the Company;
(4) such Legal Defeasance or Covenant Defeasance shall not result in a breach or
violation of, or constitute default under, any other agreement or instrument to which the
Company is a party or by which it is bound;
(5) the Company shall have delivered to the Trustee an Opinion of Counsel stating that,
as a result of such Legal Defeasance or Covenant Defeasance, neither the trust nor the
Trustee will be required to register as an investment company under the Investment Company
Act of 1940, as amended;
(6) in the case of an election under Section 9.2, the Company shall have delivered to
the Trustee an Opinion of Counsel stating that (i) the Company has received from, or there
has been published by, the Internal Revenue Service a ruling to the effect that or (ii)
there has been a change in any applicable Federal income tax law with the effect that, and
such opinion shall confirm that, the Holders of the outstanding Securities of such Series or
Persons in their positions will not recognize income, gain or loss for Federal income tax
purposes solely as a result of such Legal Defeasance and will be subject to Federal income
tax on the same amounts, in the same manner, including as a result of prepayment, and at the
same times as would have been the case if such Legal Defeasance had not occurred;
(7) in the case of an election under Section 9.3, the Company shall have delivered to
the Trustee an Opinion of Counsel to the effect that the Holders of the outstanding
Securities of such Series will not recognize income, gain or loss for Federal income tax
purposes as a result of such Covenant Defeasance, and will be subject to Federal income tax
on the same amounts, in the same manner and at the same times as would have been the case if
such Covenant Defeasance had not occurred;
(8) the Company shall have delivered to the Trustee an Officers Certificate and an
Opinion of Counsel, each stating that all conditions precedent provided for in this Article
9 relating to either the Legal Defeasance under Section 9.2 or the Covenant Defeasance under
Section 9.3 (as the case may be) have been complied with;
(9) the Company shall have delivered to the Trustee an Officers Certificate stating
that the deposit under clause (1) was not made by the Company with the intent of defeating,
hindering, delaying or defrauding any creditors of the Company or others; and
(10) the Company shall have paid, or duly provided for payment under terms mutually
satisfactory to the Company and the Trustee, all amounts then due to the Trustee pursuant to
Section 7.7.
-38-
9.5. DEPOSITED MONEY AND U.S. AND FOREIGN GOVERNMENT OBLIGATIONS TO BE HELD IN TRUST; OTHER
MISCELLANEOUS PROVISIONS.
All money, U.S. Government Obligations and Foreign Government Obligations (including the
proceeds thereof) deposited with the Trustee pursuant to Section 9.4 in respect of the outstanding
Securities shall be held in trust and applied by the Trustee, in accordance with the provisions of
such Securities and this Indenture, to the payment, either directly or through any Paying Agent as
the Trustee may determine, to the Holders of such Securities, of all sums due and to become due
thereon in respect of principal, accrued interest and premium, if any, but such money need not be
segregated from other funds except to the extent required by law.
The Company shall pay and indemnify the Trustee against any tax, fee or other charge imposed
on or assessed against the U.S. Government Obligations and Foreign Government Obligations deposited
pursuant to Section 9.4 or the principal, interest and premium, if any, received in respect thereof
other than any such tax, fee or other charge which by law is for the account of the Holders of the
outstanding Securities.
Anything in this Article 9 to the contrary notwithstanding, but subject to payment of any of
its outstanding fees and expenses, the Trustee shall deliver or pay to the Company from time to
time upon Company Request any money, U.S. Government Obligations or Foreign Government Obligations
held by the Trustee as provided in Section 9.4 which, in the opinion of a nationally-recognized
firm of independent public accountants expressed in a written certification thereof delivered to
the Trustee, are in excess of the amount thereof which would then be required to be deposited to
effect an equivalent Legal Defeasance or Covenant Defeasance.
9.6. REINSTATEMENT.
If the Trustee or Paying Agent is unable to apply any money, U.S. Government Obligations or
Foreign Government Obligations in accordance with Section 9.1, 9.2, 9.3 or 9.4 by reason of any
legal proceeding or by reason of any order or judgment of any court or governmental authority
enjoining, restraining or otherwise prohibiting such application, the Companys obligations under
this Indenture and the Securities shall be revived and reinstated as though no deposit had occurred
pursuant to this Article 9 until such time as the Trustee or Paying Agent is permitted to apply all
such money, U.S. Government Obligations or Foreign Government Obligations, as the case may be, in
accordance with Section 9.1, 9.2, 9.3 or 9.4; PROVIDED, HOWEVER, that if the Company has made any
payment of principal of, or accrued interest or premium, if any, on, any Securities because of the
reinstatement of its obligations, the Company shall be subrogated to the rights of the Holders of
such Securities to receive such payment from the money, U.S. Government Obligations or Foreign
Government Obligations held by the Trustee or Paying Agent.
9.7. MONEYS HELD BY PAYING AGENT.
In connection with the satisfaction and discharge of this Indenture, all moneys then held by
any Paying Agent under the provisions of this Indenture shall, upon demand of the Company, be paid
to the Trustee, or, if sufficient moneys have been deposited pursuant to Section 9.1, to
-39-
the Company, and thereupon such Paying Agent shall be released from all further liability with respect
to such moneys.
9.8. MONEYS HELD BY TRUSTEE.
Any moneys deposited with the Trustee or any Paying Agent or then held by the Company in trust
for the payment of the principal of, or interest or premium, if any, on, any Security that are not
applied but remain unclaimed by the Holder of such Security for two years after the date upon which
the principal of, or interest or premium, if any, on, such Security shall have respectively become
due and payable shall be repaid to the Company upon Company Request, or if such moneys are then
held by the Company in trust, such moneys shall be released from such trust; and the Holder of such
Security entitled to receive such payment shall thereafter, as an unsecured general creditor, look
only to the Company for the payment thereof, and all liability of the Trustee or such Paying Agent
with respect to such trust money shall thereupon cease; PROVIDED, HOWEVER, that the Trustee or any
such Paying Agent, before being required to make any such repayment, may, at the expense of the
Company, either mail to each Securityholder affected, at the address shown in the register of the
Securities maintained by the Registrar, or cause to be published once a week for two successive
weeks, in a newspaper published in the English language, customarily published each Business Day
and of general circulation in the City of New York, New York, a notice that such money remains
unclaimed and that, after a date specified therein, which shall not be less than 30 days from the
date of such mailing or publication, any unclaimed balance of such moneys then remaining will be
repaid to the Company. After payment to the Company or the release of any money held in trust by
the Company, Securityholders entitled to the money must look only to the Company for payment as
general creditors, unless applicable abandoned property law designates another Person.
ARTICLE 10
MISCELLANEOUS
10.1. TRUST INDENTURE ACT CONTROLS.
If any provision of this Indenture limits, qualifies or conflicts with another provision which
is required to be included in this Indenture by the TIA, the required provision shall control. If
any provision of this Indenture modifies or excludes any provision of the TIA which may be so
modified or excluded, the latter provision shall be deemed to apply to this Indenture as so
modified or to be excluded, as the case may be.
10.2. NOTICES.
Any notice or communication shall be given in writing and delivered in Person, sent by
facsimile (and receipt confirmed by telephone or electronic transmission report), delivered by
commercial courier service or mailed by first-class mail, postage prepaid, addressed as follows:
-40-
If to the Company:
Amicus Therapeutics, Inc.
6 Cedar Brook Drive
Cranbury, New Jersey 08512
Fax: (609) 662-2001
Attention: General Counsel
Copy to:
Bingham McCutchen
One Federal Street
Boston, Massachusetts 02110
Fax: (617) 428-6340
Attention: Meerie M. Joung, Esq.
If to the Trustee:
The Company or the Trustee by written notice to the other may designate additional or
different addresses for subsequent notices or communications. Any notice or communication to the
Company or the Trustee shall be deemed to have been given or made as of the date so delivered if
personally delivered; when receipt is confirmed by telephone or electronic transmission report, if
sent by facsimile; and three Business Days after mailing if sent by registered or certified mail,
postage prepaid (except that a notice of change of address shall not be deemed to have been given
until actually received by the addressee).
Any notice or communication mailed to a Securityholder shall be mailed to such Securityholder
by first-class mail, postage prepaid, at such Securityholders address shown on the register kept
by the Registrar.
Failure to mail, or any defect in, a notice or communication to a Securityholder shall not
affect its sufficiency with respect to other Securityholders. If a notice or communication to a
Securityholder is mailed in the manner provided above, it shall be deemed duly given, three
Business Days after such mailing, whether or not the addressee receives it.
In case by reason of the suspension of regular mail service, or by reason of any other cause,
it shall be impossible to mail any notice as required by this Indenture, then such method of
notification as shall be made with the approval of the Trustee shall constitute a sufficient
mailing of such notice.
In the case of Global Securities, notices or communications to be given to Securityholders
shall be given to the Depository, in accordance with its applicable policies as in effect from time
to time.
-41-
In addition to the manner provided for in the foregoing provisions, notices or communications
to Securityholders shall be given by the Company by release made to Reuters Economic Services and
Bloomberg Business News.
10.3. COMMUNICATIONS BY HOLDERS WITH OTHER HOLDERS.
Securityholders of any Series may communicate pursuant to TIA Section 312(b) with other
Securityholders of that Series or any other Series with respect to their rights under this
Indenture or the Securities of that Series or any other Series. The Company, the Trustee, the
Registrar and any other Person shall have the protection of TIA Section 312(c).
10.4. CERTIFICATE AND OPINION AS TO CONDITIONS PRECEDENT.
Upon any request or application by the Company to the Trustee to take any action under this
Indenture, the Company shall furnish to the Trustee:
(1) an Officers Certificate (which shall include the statements set forth in Section
10.5 below) stating that, in the opinion of the signers, all conditions precedent, if any,
provided for in this Indenture relating to the proposed action have been complied with; and
(2) an Opinion of Counsel (which shall include the statements set forth in Section 10.5
below) stating that, in the opinion of such counsel, all such conditions precedent have been
complied with.
10.5. STATEMENT REQUIRED IN CERTIFICATE AND OPINION.
Each certificate and opinion with respect to compliance with a condition or covenant provided
for in this Indenture (other than pursuant to Section 4.4) shall include:
(1) a statement that the Person making such certificate or opinion has read such
covenant or condition;
(2) a brief statement as to the nature and scope of the examination or investigation
upon which the statements or opinions contained in such certificate or opinion are based;
(3) a statement that, in the opinion of such Person, it or he has made such examination
or investigation as is necessary to enable it or him to express an informed opinion as to
whether or not such covenant or condition has been complied with; and
(4) a statement as to whether or not, in the opinion of such Person, such covenant or
condition has been complied with.
10.6. RULES BY TRUSTEE AND AGENTS.
The Trustee may make reasonable rules for action by or at meetings of Securityholders. The
Registrar and Paying Agent may make reasonable rules for their functions.
-42-
10.7. BUSINESS DAYS; LEGAL HOLIDAYS; PLACE OF PAYMENT.
A Business Day is a day that is not a Legal Holiday. A Legal Holiday is a Saturday, a
Sunday, a federally-recognized holiday or a day on which banking institutions are not authorized or
required by law, regulation or executive order to be open in the State of New York.
If a payment date is a Legal Holiday at a Place of Payment, payment may be made at that place
on the next succeeding day that is not a Legal Holiday, and no interest shall accrue for the
intervening period. Place of Payment means the place or places where the principal of, and
interest and premium, if any, on, the Securities of a Series are payable as specified as
contemplated by Section 2.2. If the regular record date is a Legal Holiday, the record date shall
not be affected.
10.8. GOVERNING LAW.
THIS INDENTURE AND THE SECURITIES SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF NEW YORK, AS APPLIED TO CONTRACTS MADE AND PERFORMED WITHIN THE STATE OF NEW
YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW.
10.9. NO ADVERSE INTERPRETATION OF OTHER AGREEMENTS.
This Indenture may not be used to interpret another indenture, loan, security or debt
agreement of the Company or any Subsidiary thereof. No such indenture, loan, security or debt
agreement may be used to interpret this Indenture.
A director, officer, employee, stockholder or incorporator, as such, of the Company shall not
have any liability for any obligations of the Company under the Securities or the Indenture. Each
Securityholder by accepting a Security waives and releases all such liability. Such waiver and
release are part of the consideration for the issuance of the Securities.
10.10. SUCCESSORS.
All covenants and agreements of the Company in this Indenture and the Securities shall bind
the Companys successors and assigns, whether so expressed or not. All agreements of the Trustee,
any additional trustee and any Paying Agents in this Indenture shall bind their respective
successors and assigns.
10.11. MULTIPLE COUNTERPARTS.
The parties may sign multiple counterparts of this Indenture. Each signed counterpart shall be
deemed an original, but all of them together represent one and the same agreement.
-43-
10.12. TABLE OF CONTENTS, HEADINGS, ETC.
The table of contents, cross-reference sheet and headings of the Articles and Sections of this
Indenture have been inserted for convenience of reference only, are not to be considered a part
hereof, and shall in no way modify or restrict any of the terms or provisions hereof.
10.13. SEVERABILITY.
Each provision of this Indenture shall be considered separable, and if for any reason any
provision which is not essential to the effectuation of the basic purpose of this Indenture or the
Securities shall be invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions shall not in any way be affected or impaired thereby, and a Holder shall
have no claim therefor against any party hereto.
10.14. SECURITIES IN A FOREIGN CURRENCY OR IN EUROS.
Unless otherwise specified in a Board Resolution, a supplemental indenture hereto or an
Officers Certificate delivered pursuant to Section 2.2 with respect to a particular Series of
Securities, whenever for purposes of this Indenture any action may be taken by the Holders of a
specified percentage in aggregate principal amount of Securities of all Series or all Series
affected by a particular action at the time outstanding and, at such time, there are outstanding
Securities of any Series which are denominated in a coin or currency other than Dollars (including
Euros), then the principal amount of Securities of such Series which shall be deemed to be
outstanding for the purpose of taking such action shall be that amount of Dollars that could be
obtained for such amount at the Market Exchange Rate at such time. For purposes of this Section
10.15, Market Exchange Rate shall mean the noon Dollar buying rate in New York City for cable
transfers of that currency as published by the Federal Reserve Bank of New York; PROVIDED, HOWEVER,
in the case of Euros, Market Exchange Rate shall mean the rate of exchange determined by the
Commission of the European Union (or any successor thereto) as published in the Official Journal of
the European Union (such publication or any successor publication, the Journal). If such Market
Exchange Rate is not available for any reason with respect to such currency, the Trustee shall use,
in its sole discretion and without liability on its part, such quotation of the Federal Reserve
Bank of New York or, in the case of Euros, the rate of exchange as published in the Journal, as of
the most recent available date, or quotations or, in the case of Euros, rates of exchange from one
or more major banks in New York City or in the country of issue of the currency in question or, in
the case of Euros, in Luxembourg or such other quotations or, in the case of Euros, rates of
exchange as the Trustee, upon consultation with the Company, shall deem appropriate. The provisions
of this paragraph shall apply in determining the equivalent principal amount in respect of
Securities of a Series denominated in currency other than Dollars in connection with any action
taken by Holders of Securities pursuant to the terms of this Indenture.
All decisions and determinations of the Trustee regarding the Market Exchange Rate or any
alternative determination provided for in the preceding paragraph shall be in the Trustees sole
discretion, and shall, in the absence of manifest error, be conclusive to the extent permitted by
law for all purposes and irrevocably binding upon the Company and all Holders.
-44-
10.15. JUDGMENT CURRENCY.
The Company agrees, to the fullest extent that it may effectively do so under applicable law,
that (a) if for the purpose of obtaining judgment in any court it is necessary to convert the sum
due in respect of the principal of, or interest or premium, if any, or other amount on, the
Securities of any Series (the Required Currency) into a currency in which a judgment will be
rendered (the Judgment Currency), the rate of exchange used shall be the rate at which, in
accordance with normal banking procedures, the Trustee could purchase in The City of New York the
Required Currency with the Judgment Currency on the day on which final unappealable judgment is
entered, unless such day is not a Business Day, in which instance, the rate of exchange used shall
be the rate at which, in accordance with normal banking procedures, the Trustee could purchase in
The City of New York the Required Currency with the Judgment Currency on the Business Day preceding
the day on which final unappealable judgment is entered and (b) its obligations under this
Indenture to make payments in the Required Currency (i) shall not be discharged or satisfied by any
tender or any recovery pursuant to any judgment (whether or not entered in accordance with
subsection (a)) in any currency other than the Required Currency, except to the extent that such
tender or recovery shall result in the actual receipt, by the payee, of the full amount of the
Required Currency expressed to be payable in respect of such payments, (ii) shall be enforceable as
an alternative or additional cause of action for the purpose of recovering in the Required Currency
the amount, if any, by which such actual receipt shall fall short of the full amount of the
Required Currency so expressed to be payable and (iii) shall not be affected by judgment being
obtained for any other sum due under this Indenture.
-45-
IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed,
and their respective corporate seals to be hereunto affixed and attested, all as of the day and
year first above written.
|
|
|
|
|
|
|
AMICUS THERAPEUTICS, INC. |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
|
|
|
Name: |
|
|
|
|
|
|
|
|
|
Title: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
[Name of Trustee] |
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
|
|
|
Name: |
|
|
|
|
|
|
|
|
|
Title: |
|
|
|
|
|
|
|
|
|
By: |
|
|
|
|
|
|
|
|
|
Name: |
|
|
|
|
|
|
|
|
|
Title: |
|
|
|
|
|
|
|
EX-5.1
Exhibit 5.1
April 3, 2009
Amicus Therapeutics, Inc.
6 Cedar Brook Drive
Cranbury, New Jersey 08512
Re: Registration Statement on Form S-3
Ladies and Gentlemen:
We have acted as counsel to Amicus Therapeutics, Inc., a Delaware corporation (the
Company), in connection with the Companys registration statement on Form S-3 (the Registration
Statement), including the prospectus that is part of the Registration Statement (the
Prospectus), filed on the date hereof, with the Securities and Exchange Commission (the
Commission) under the Securities Act of 1933, as amended (the Securities Act). The Prospectus
provides that it will be supplemented in the future by one or more prospectus supplements (each, a
Prospectus Supplement). The Prospectus, as supplemented by the various Prospectus Supplements,
will provide for the issuance and sale by: (A) the Company from time to time of (i) shares of
common stock, $0.01 par value per share (the Common Stock), (ii) shares of the Companys
preferred stock, $0.01 par value per share (the Preferred Stock), (iii) one or more series of the
debt securities of the Company, which may be convertible into or exchangeable for shares of Common
Stock and/or Preferred Stock (the Debt Securities), (iv) warrants to purchase shares of Common
Stock, shares of Preferred Stock and/or Debt Securities (the Warrants), (v) shares of Common
Stock and/or Preferred Stock issuable upon exercise of the Warrants, and/or (vi) any combination of
the foregoing, and (B) those certain stockholders of the Company identified in the Prospectus as
Selling Stockholders (the Selling Stockholders) from time to time of the Common Stock identified
as being beneficially owned by such Selling Stockholders in the Prospectus (the Selling
Stockholders Shares). The Common Stock, the Preferred Stock, the Debt Securities and the Warrants
are herein referred to as the Registered Securities. The Registered Securities may be offered
and sold by the Company from time to time pursuant to Rule 415 under the Securities Act as set
forth in the Prospectus, as supplemented by the various Prospectus Supplements that may be filed
under the Securities Act. The Selling Stockholders Shares may be sold by the Selling Stockholders
from time to time pursuant to Rule 415 under the Securities Act as set forth in the Prospectus, as
supplemented by the various Prospectus Supplements that may be filed under the Securities Act.
This opinion letter is furnished to you at your request to enable you to fulfill the requirements
of
Amicus Therapeutics, Inc.
April 3, 2009
Page 2
Item 601(b)(5) of Regulation S-K, in connection with the filing of the Registration Statement.
The Debt Securities will be issued pursuant to one or more indentures in the form filed as an
exhibit to the Registration Statement, as amended or supplemented from time to time (each, and
Indenture), between the Company, as obligor, and a trustee chosen by the Company and qualified to
act as such under the Trust Indenture Act of 1939, as amended (the Trustee).
We have reviewed the corporate proceedings taken by the Company with respect to the
registration of the Registered Securities. We have also examined and relied upon originals or
copies of such corporate records, documents, agreements or other instruments of the Company, and
such certificates and records of public officials, and such other papers, as we have deemed
necessary or appropriate in connection herewith. As to all matters of fact (including, without
limitation, factual conclusions and characterizations and descriptions of purpose, intention or
other state of mind including our opinion expressed in paragraph 5 below, insofar as it relates to
the Selling Stockholders Shares being fully paid) we have relied entirely upon certificates of
officers of the Company, and have assumed, without independent inquiry, the accuracy of those
certificates.
For purposes of this opinion letter, we have assumed that:
(i) the issuance, sale, amount, and terms of each of the Registered Securities to be offered
from time to time by the Company will be duly authorized and established by proper action of the
Board of Directors of the Company, and in accordance with the Restated Certificate of Incorporation
of the Company, as amended from time to time, the Restated By-laws of the Company as amended from
time to time, and applicable Delaware law, and that, at the time of each such issuance and sale of
such Registered Securities, the Company will continue to be validly existing and in good standing
under the laws of the State of Delaware, with the requisite corporate power and authority to issue
and sell all such Registered Securities at such time;
(ii) any shares of Common Stock issued by the Company pursuant to the Registration Statement,
the Prospectus and the related Prospectus Supplement, from time to time will not exceed the maximum
authorized number of shares of Common Stock under the Restated Certificate of Incorporation of the
Company, as the same may have been amended, minus that number of shares of Common Stock that may
have been issued and are outstanding, or are reserved for issuance for other purposes, at such
time;
Amicus Therapeutics, Inc.
April 3, 2009
Page 3
(iii) any shares of Preferred Stock issued pursuant to the Registration Statement, the
Prospectus and the related Prospectus Supplement, from time to time will not exceed the maximum
authorized number of shares of Preferred Stock under the Restated Certificate of Incorporation of
the Company, as the same may have been amended, minus that number of shares of Preferred Stock that
may have been issued and are outstanding, or are reserved for issuance for other purposes, at such
time;
(iv) any Warrants issued by the Company pursuant to the Registration Statement, the Prospectus
and the related Prospectus Supplement, from time to time, will be issued under one or more valid,
binding, and enforceable warrant agreements (each a Warrant Agreement); and
(v) any Debt Securities issued by the Company pursuant to the Registration Statement, the
Prospectus and the related Prospectus Supplement, from time to time, will be issued under and in
conformity with, a valid, binding and enforceable Indenture, which shall be delivered by the
Trustee, and the Trustee will have all requisite power and authority to effect the transactions
contemplated by such Indenture, and the Trustee or an authenticating agent for the trustee will
duly authenticate the Debt Securities pursuant to the applicable Indenture, and the applicable
Indenture will be the valid and binding obligation of the Trustee and will be enforceable against
the Trustee in accordance with its terms. We are expressing no opinion herein as to the application
of or compliance with any foreign, federal or state law or regulation to the power, authority or
competence of any party, other than the Company, to the applicable Indenture.
Subject to the limitations set forth below, we have made such examination of law as we have
deemed necessary for the purposes of expressing the opinions set forth in this letter. Such
opinions are limited solely to the General Corporation Law of the State of Delaware as applied by
courts located in Delaware, the applicable provisions of the Delaware Constitution and the reported
judicial decisions interpreting those laws.
Based upon the foregoing, we are of the opinion that:
1. Following effectiveness of the Registration Statement, the shares of Common Stock
registered under the Registration Statement, when duly authorized and issued against the full
payment specified therefor, which must have a value not less than the par value thereof, will be
validly issued, fully paid and nonassessable.
2. Following effectiveness of the Registration Statement, the shares of Preferred Stock
registered under the Registration Statement, when duly
Amicus Therapeutics, Inc.
April 3, 2009
Page 4
authorized and issued against the full
payment specified therefor, which must have a value not less than the par value thereof, will be
validly issued, fully paid and nonassessable.
3. Following effectiveness of the Registration Statement, the Warrants registered under the
Registration Statement, when duly authorized, executed and delivered against the payment specified
therefor, and pursuant to a Warrant Agreement or agreements duly authorized, executed and delivered
by the Company and the holder of the Warrants, will be validly issued.
4. Following effectiveness of the Registration Statement, the Debt Securities registered under
the Registration Statement, when duly authorized, executed and delivered against the payment
specified therefor, and pursuant to an Indenture or agreements duly authorized, executed and
delivered by the Company and the holder of the Warrants, will be validly issued.
5. The Selling Stockholders Shares have been duly authorized and are validly issued, fully
paid and nonassessable.
This opinion letter is given as of the date hereof, and we express no opinion as to the effect
of subsequent events or changes in law occurring or becoming effective after the date hereof. We
assume no obligation to update this opinion letter or otherwise advise you with respect to any
facts or circumstances or changes in law that may hereafter occur or come to our attention.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement
and to the reference to this firm under the heading Legal Matters in the Prospectus included in
the Registration Statement. In rendering this opinion and giving this consent, we do not admit that
we are an expert within the meaning of the Securities Act.
|
|
|
|
|
|
Very truly yours,
|
|
|
/s/ Bingham McCutchen LLP
|
|
|
BINGHAM McCUTCHEN LLP |
|
|
|
|
|
EX-12.1
Exhibit 12.1
Amicus Therapeutics, Inc.
Ratio of Earnings to Fixed Charges (1)
(dollar amounts in thousands except for ratio)
(excludes discontinued operations for all periods)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, |
|
|
|
2004 |
|
|
2005 |
|
|
2006 |
|
|
2007 |
|
|
2008 |
|
Net loss from
continuing
operations |
|
$ |
(8,807 |
) |
|
$ |
(19,972 |
) |
|
$ |
(46,345 |
) |
|
$ |
(41,167 |
) |
|
$ |
(39,355 |
) |
|
|
Fixed charges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
550 |
|
|
|
82 |
|
|
|
273 |
|
|
|
348 |
|
|
|
218 |
|
Estimate of
interest within
rental expense |
|
|
51 |
|
|
|
324 |
|
|
|
524 |
|
|
|
611 |
|
|
|
658 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total fixed charges |
|
|
601 |
|
|
|
406 |
|
|
|
797 |
|
|
|
959 |
|
|
|
876 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deficiency of
earnings available
to cover fixed
charges
(2) |
|
$ |
(8,206 |
) |
|
$ |
(19,566 |
) |
|
$ |
(45,548 |
) |
|
$ |
(40,208 |
) |
|
$ |
(38,479 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ratio of earnings
to fixed charges |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The ratio of earnings to fixed charges is defined as earnings divided by fixed
charges. For purposes of this ratio, earnings is defined as net loss from continuing
operations plus fixed charges. Fixed charges are defined as the sum of interest expense
and the estimate of interest within rental expense. |
|
(2) |
|
For the years ended December 31, 2004, 2005, 2006, 2007 and 2008, earnings were
insufficient to cover fixed charges by $8.8 million, $20.0 million, $46.3 million, $41.2
million and $39.4 million, respectively. |
EX-23.2
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the reference to our firm under the caption Experts in the Registration Statement
on Form S-3 and related prospectus of Amicus Therapeutics, Inc. (the Company) for the
registration of common stock, preferred stock, warrants and debt securities and to the
incorporation by reference therein of our report dated February 4, 2009, with respect to the
consolidated financial statements of the Company included in the Companys Annual Report on Form
10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission on
February 5, 2009.
MetroPark, New Jersey
April 2, 2009
COVER LETTER
April 3, 2009
Via Edgar (correspondence)
Securities and Exchange Commission
Securities & Exchange Commission
100 F. Street, N.E.
Judiciary Plaza
Washington, D.C. 20549
Re: Amicus Therapeutics, Inc. - Registration Statement on Form S-3
Ladies and Gentlemen:
Amicus Therapeutics, Inc. (the Company), hereby transmits via EDGAR for filing under the
Securities Act of 1933, as amended (the Act), a Registration Statement of the Company on Form S-3
(the Registration Statement), with respect to a proposed registration by the Company with an
aggregate value of up to $100,000,000 which may include a presently undesignated number of (i)
shares of common stock, $0.01 par value per share (the Common Stock), (ii) shares of the
Companys preferred stock, $0.01 par value per share (the Preferred Stock), (iii) one or more
series of the debt securities of the Company, which may be convertible into or exchangeable for
shares of Common Stock and/or Preferred Stock (the Debt Securities), (iv) warrants to purchase
shares of Common Stock, shares of Preferred Stock and/or Debt Securities (the Warrants), (v)
shares of Common Stock and/or Preferred Stock issuable upon exercise of the Warrants, and/or (vi)
any combination of the foregoing, and with respect those certain stockholders of the Company
identified in the prospectus as selling stockholders (the Selling Stockholders) from time to time
of the Common Stock identified as being beneficially owned by such Selling Stockholders in the
prospectus. Enclosed with this letter for filing pursuant to the Securities Act of 1933, as
amended (the Act), is the Registration Statement, together with all exhibits thereto.
The Company has paid a filing fee of $5,580 by wire transfer in connection with the filing of
the Registration Statement. This fee was paid pursuant to Rule 457(o) under the Act.
Please call the undersigned at (609) 662-5067, if you have any questions or require any
additional information. Questions on accounting matters may be addressed to James E. Dentzer, the
Chief Financial Officer of the Company, at (609) 336-1161.
|
|
|
|
|
|
Very truly yours,
/S/ PETER M. MACALUSO
Peter M. Macaluso
|
|
|
|
|
|
|
|
|
|
|
|
Enclosure
|
|
|
|
|
|
|
|
|
|
|
|
|
cc: |
|
Meerie Joung, Esq. |
|
) |
|
|
|
|
|
|
|
|
Julio E. Vega, Esq. |
|
) |
|
Bingham McCutchen LLP |
|
|
Jason M. Rodriguez, Esq. |
|
) |
|
|
|
|
|
|